

1 Title: SARS-CoV-2 infection leads to acute infection with dynamic cellular and inflammatory flux  
2 in the lung that varies across nonhuman primate species

3 Authors: Dhiraj Kumar Singh<sup>1,2</sup>, Shashank R. Ganatra<sup>1,2</sup>, Bindu Singh<sup>1,2</sup>, Journey Cole<sup>1,2</sup>, Kendra J.  
4 Alfson<sup>2</sup>, Elizabeth Clemmons<sup>1,2</sup>, Michal Gazi<sup>2</sup>, Olga Gonzalez<sup>1,2</sup>, Ruby Escobedo<sup>1,2</sup>, Tae-Hyung  
5 Lee<sup>1,2</sup>, Ayan Chatterjee<sup>1,2</sup>, Yenny Goez-Gazi<sup>2</sup>, Riti Sharan<sup>1,2</sup>, Rajesh Thippeshappa<sup>1,2</sup>, Maya  
6 Gough<sup>1,2</sup>, Cynthia Alvarez<sup>1,2</sup>, Alyssa Blakley<sup>1,2</sup>, Justin Ferdin<sup>1,2</sup>, Carmen Bartley<sup>1,2</sup>, Hilary Staples<sup>1,2</sup>,  
7 Laura Parodi<sup>1,2</sup>, Jessica Callery<sup>1,2</sup>, Amanda Mannino<sup>1,2</sup>, Benjamin Klaffke<sup>2</sup>, Priscilla Escareno<sup>2</sup>, Roy  
8 N. Platt II<sup>2</sup>, Vida Hodara<sup>1,2</sup>, Julia Scordo<sup>2</sup>, Adelekan Oyejide<sup>3</sup>, Dharani K. Ajithdoss<sup>3</sup>, Richard Copin<sup>3</sup>,  
9 Alina Baum<sup>3</sup>, Christos Kyratsous<sup>3</sup>, Xavier Alvarez<sup>1,2</sup>, Bruce Rosas<sup>4</sup>, Mushtaq Ahmed<sup>4</sup>, Anna  
10 Goodroe<sup>1,2</sup>, John Dutton<sup>1,2</sup>, Shannan Hall-Ursone<sup>1,2</sup>, Patrice A. Frost<sup>1,2</sup>, Andra K. Voges<sup>5</sup>, Corinna  
11 N. Ross<sup>1,2</sup>, Ken Sayers<sup>1,2</sup>, Christopher Chen<sup>1,2</sup>, Cory Hallam<sup>2</sup>, Shabaana A. Khader<sup>4</sup>, Makedonka  
12 Mitreva<sup>4</sup>, Timothy J. C. Anderson<sup>2</sup>, Luis Martinez-Sobrido<sup>2</sup>, Jean L. Patterson<sup>2</sup>, Joanne Turner<sup>2</sup>,  
13 Jordi B.Torrelles<sup>2</sup>, Edward J. Dick, Jr.<sup>1,2</sup>, Kathleen Brasky<sup>1,2</sup>, Larry S. Schlesinger<sup>1,2</sup>, Luis D.  
14 Giavedoni<sup>1,2#</sup>, Ricardo Carrion, Jr.<sup>1,2#</sup>, Deepak Kaushal<sup>1,2#</sup>

15 Affiliations: <sup>1</sup>Southwest National Primate Research Center, <sup>2</sup>Texas Biomedical Research Institute,  
16 San Antonio, TX, 78227, <sup>3</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; <sup>4</sup>Washington  
17 University in St Louis School of Medicine, St Louis, MO; <sup>5</sup>Veterinary Imaging Consulting of South  
18 Texas, San Antonio, TX, 78258.

19 #To whom correspondence may be addressed: Deepak Kaushal, PhD, Director, Southwest  
20 National Primate Research Center, Professor, Texas Biomedical Research Institute, 8715 W.  
21 Military Drive, San Antonio, TX, 78227, Email: [dkaushal@txbiomed.org](mailto:dkaushal@txbiomed.org), Tel. (210)258-9209; OR  
22 Ricardo Carrion, Jr., PhD, Professor, Texas Biomedical Research Institute, 8715 W. Military Drive,

23 San Antonio, TX, 78227; Email: [rcarrion@txbiomed.org](mailto:rcarrion@txbiomed.org), Tel. (210)258-9479 OR Luis D. Giavedoni,  
24 PhD, Professor, Texas Biomedical Research Institute, 8715 W. Military Drive, San Antonio, TX,  
25 78227, Email: [lgiavedoni@txbiomed.org](mailto:lgiavedoni@txbiomed.org), Tel. (210)258-9603.

26 Abbreviations: COVID-19, Coronavirus disease 2019; SARS-CoV-2, Severe Acute Respiratory  
27 Syndrome Coronavirus-2; BAL, bronchoalveolar lavage; PFU, Plaque Forming Unit; CRP, C-  
28 reactive protein; CXR, thoracic radiograph; NHP, nonhuman primate; PBMC, peripheral blood  
29 mononuclear cell; dpi, days post-infection.

30 Key words: COVID-19, SARS-CoV-2, nonhuman primates, rhesus macaques, baboons, marmosets,  
31 animal models, BAL, CT

32

### 33 **Summary**

34 There are no known cures or vaccines for COVID-19, the defining pandemic of this era. Animal  
35 models are essential to fast track new interventions and nonhuman primate (NHP) models of  
36 other infectious diseases have proven extremely valuable. Here we compare SARS-CoV-2  
37 infection in three species of experimentally infected NHPs (rhesus macaques, baboons, and  
38 marmosets). During the first 3 days, macaques developed clinical signatures of viral infection and  
39 systemic inflammation, coupled with early evidence of viral replication and mild-to-moderate  
40 interstitial and alveolar pneumonitis, as well as extra-pulmonary pathologies. Cone-beam CT  
41 scans showed evidence of moderate pneumonia, which progressed over 3 days. Longitudinal  
42 studies showed that while both young and old macaques developed early signs of COVID-19, both  
43 groups recovered within a two-week period. Recovery was characterized by low-levels of viral  
44 persistence in the lung, suggesting mechanisms by which individuals with compromised immune

45 systems may be susceptible to prolonged and progressive COVID-19. The lung compartment  
46 contained a complex early inflammatory milieu with an influx of innate and adaptive immune  
47 cells, particularly interstitial macrophages, neutrophils and plasmacytoid dendritic cells, and a  
48 prominent Type I-interferon response. While macaques developed moderate disease, baboons  
49 exhibited prolonged shedding of virus and extensive pathology following infection; and  
50 marmosets demonstrated a milder form of infection. These results showcase in critical detail, the  
51 robust early cellular immune responses to SARS-CoV-2 infection, which are not sterilizing and  
52 likely impact development of antibody responses. Thus, various NHP genera recapitulate  
53 heterogeneous progression of COVID-19. Rhesus macaques and baboons develop different,  
54 quantifiable disease attributes making them immediately available essential models to test new  
55 vaccines and therapies.

56

## 57 **Main**

58 A novel coronavirus, designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),  
59 emerged in Wuhan, China in 2019, and was proven to be the cause of an unspecified pneumonia.  
60 It has since spread globally, causing Coronavirus Disease 2019 (COVID-19) <sup>1</sup>. The World Health  
61 Organization (WHO) declared COVID-19 a pandemic. It is clear that community spread of SARS-  
62 CoV-2 is occurring rapidly and the virus has very high infectivity and transmission rates, even  
63 compared to SARS-CoV-1, the causative agent of an outbreak 15 years earlier. It has been  
64 estimated that between up to 250,000 American lives may be lost due to COVID-19. The world  
65 over, these numbers could be 10-50 times worse. Clearly, COVID-19 is the most defining

66 pandemic of this era, requiring significant biomedical research input, in order to most effectively  
67 fast track the development of new therapies and vaccines.

68

69 Human COVID-19 disease presents with a broad clinical spectrum ranging from asymptomatic to  
70 mild and severe cases. Patients with COVID pneumonia exhibit high-grade pyrexia, fatigue,  
71 dyspnea and dry cough accompanied by a rapidly progressing pneumonia, with bilateral opacities  
72 on x-ray and patchy, ground glass opacities on lung Computed Tomography (CT) scans. Individuals  
73 with immunocompromised conditions and comorbidities are at highest risk for worse outcomes  
74 of COVID-19.

75

76 Nonhuman primate (NHP) models of infectious diseases have proven useful for both investigating  
77 the pathogenesis of infection and testing therapeutic and vaccine candidates<sup>2</sup>. During the SARS  
78 and MERS outbreaks, NHP models were developed with a moderate degree of success<sup>3</sup>. Early  
79 reports also indicate the utility of NHPs for SARS-CoV-2 infection, and for evaluating vaccine  
80 candidates<sup>4,5,6,7</sup>. We hypothesized that the heterogeneity of human responses to SARS-CoV-2  
81 infection can be recapitulated using multiple NHP species. Furthermore, we sought to gain a  
82 detailed characterization of the early cellular immune events following SARS-CoV-2 infection in  
83 the lung compartment, which has not yet been reported. Here, we compare SARS-CoV-2 infection  
84 in three species of NHPs (Specific Pathogen-free [SPF] Indian rhesus macaques, African-origin  
85 baboons, and New-World origin common marmosets). We assess age as a variable and focus our  
86 studies on high resolution imaging and the critical nature of the early cellular immune response  
87 in the lung which likely impacts disease outcome.

88

### 89 **Early events in SARS-CoV-2 infection in rhesus macaques**

90 We first assessed the ability of SARS-CoV-2 to infect rhesus macaques during an acute 3-day  
91 infection study. Four Indian-origin mycobacteria- and SPF-naïve rhesus macaques (*Macaca*  
92 *mulatta*) (Table S1) were infected by multiple routes (ocular, intratracheal and intranasal) with  
93 sixth-passage virus at a target dose of  $1.05 \times 10^6$  PFU/per animal. All animals developed clinical  
94 signs of viral infection as evidenced by a doubling of serum C-Reactive Protein (CRP) levels  
95 relative to baseline, indicating systemic inflammation (Fig 1a); significantly decreased serum  
96 albumin (Fig 1b) and hemoglobin (Fig 1c) levels, indicating viral-induced anemia; and  
97 progressively increasing total serum CO<sub>2</sub> levels (Fig S1a) indicative of pulmonary dysfunction.  
98 These observations were accompanied by a decrease in red blood cells (RBCs) (Fig S1b),  
99 reticulocytes (Fig S1c), white blood cells (WBCs) (Fig S1d), and platelet counts (Fig S1e); and a  
100 decrease in both the total number and percentage of neutrophils (Fig S1f, g), the latter suggesting  
101 that neutrophils are recruited to the lung compartment in response to SARS-CoV-2 infection as  
102 first responders. In contrast, systemic influx of monocytes was observed, indicating viral  
103 infection-induced myelopoiesis (Fig S1h). Monocytes are crucial for successful antiviral responses  
104 via recognition of pathogen-associated molecular patterns, thereby initiating a signaling cascade  
105 that invokes an interferon response to control infections. No significant pyrexia or weight loss  
106 was observed in this acute study. Overall, our results suggest that rhesus macaques develop  
107 several clinical signs of viral infection following experimental exposure to SARS-CoV-2.

108

109 Viral RNA was detected in BAL, and from nasal or nasopharyngeal (NS) and buccopharyngeal (BS)  
110 swabs at 1-3 days post-infection (dpi), but not at pre-infection time points (Fig 1d-f). Viral RNA  
111 was also detected in saliva and from rectal swabs (RS) in a small subset of animals (Fig S1i-j).  
112 Unlike other samples, viral RNA was only detected in RS at later time points (i.e., after 1 dpi). At  
113 necropsy (3 dpi), we performed random sampling from every lung lobe and SARS-CoV-2 RNA  
114 could be detected in 23/24 total lung sections analyzed. An average of 4-6 log copies/100 mg of  
115 lung tissue could be detected from every lobe (Fig 1g). The ~4-log increase in viral RNA from 1 to  
116 2 dpi in the BAL (Fig 1d) provided clear evidence of early active replication of SARS-CoV-2 in  
117 rhesus macaques.

118  
119 Examination at necropsy (3 dpi) revealed findings of interstitial and alveolar pneumonia (Fig 1h,  
120 i). While gross appearance of the lungs of most infected animals was unremarkable (Fig S2a),  
121 multifocal to coalescing red discoloration of the left lung lobes in one macaque was observed (Fig  
122 S2b). Table S2 summarizes the histopathologic findings in descending order of occurrence by  
123 anatomic location. The lung was the most affected organ ((Fig 1h, i, Table S2, Fig S2). Multifocal,  
124 mild to moderate interstitial pneumonia characterized by infiltrates of neutrophils, macrophages,  
125 lymphocytes, and eosinophils was present in all four animals (Fig 1 i, Fig S2d, e, g, h), and was  
126 accompanied by variable fibrosis (4/4, Fig S2e), fibrin deposition (3/4, Fig S2c), vasculitis (3/4, Fig  
127 S2f), edema (2/4, Fig S2h), necrosis (Fig S2g), and areas of consolidation (2/4, Fig S2c). All four  
128 macaques exhibited the following: 1) Syncytial cells in the epithelial lining and/or alveolar lumen  
129 (Fig S2e, g, k); 2) Bronchitis characterized by infiltrates of eosinophils within the bronchial wall

130 and epithelium (Fig 1h, Fig S2i, j, k); Bronchus-associated lymphoid tissue (BALT) hyperplasia (Fig  
131 S2i); and 4) Minimal to moderate lymphoplasmacytic and eosinophilic tracheitis and rhinitis.

132

133 The presence of SARS-CoV-2 in tissue sections collected at necropsy (3 dpi) was determined by  
134 multi-label confocal immunofluorescence using antibodies specific for Nucleocapsid (N) (Fig 1j,  
135 k, Fig S3) and Spike(S) proteins (Fig S4) and their respective isotype controls (Fig S3, S4).

136 Fluorescence immuno-histochemical analysis revealed the presence of SARS CoV-2 proteins in  
137 lungs (Fig 1j, Fig S3a, g, Fig S4a, d, g, j), nasal epithelium (Fig 1k, Fig S3b, h, Fig S4b, e, h, k) and  
138 tonsils (Fig S3c, i, Fig S4c, f, l, l). In all tissues, including lungs (Fig 1j, Fig S3 a, g), nasal epithelium

139 (Fig 1k, Fig S3 b, h) and tonsils (Fig S3 c, i), N antigen signal was present in cells expressing ACE2,  
140 which has been shown to be a receptor for SARS-CoV-2, or in cells adjoining those expressing  
141 ACE2. No signal was detected in N isotype control staining in lungs, nasal epithelium or tonsils

142 (Fig S3d-f), and no signal for viral antigen was detected in naïve tissues (Fig S3 m, n). It appeared  
143 that the expression levels of ACE2 protein were much lower in lung tissues derived from naïve  
144 animals compared to those from macaques exposed to SARS-CoV-2 (Fig S3 m, n). The majority of

145 the S signal was detected in the epithelial layer with discrete distribution throughout the lung  
146 tissue (Fig S4a, d). In the nasal cavity, the virus was observed in cells of the epithelial linings (Fig  
147 S4b, h) but in tonsils, the virus appeared distributed throughout the tissue (Fig 3c, i). Together,

148 these results show that SARS-CoV-2 exposure induces a respiratory tract infection in rhesus  
149 macaques. Viral replication is supported in the upper and lower lung compartments during the  
150 first three days of infection and viral antigens are detected at high levels in the lungs.

151

152 To complement the lung histopathology in rhesus macaques, radiographs were performed at  
153 baseline and each day post-infection. All four infected macaques showed progressive increase in  
154 CXR abnormality scores, consistent with an infectious disease (Fig 2a, Fig S5a). The 2 and 3 dpi  
155 CXR scores were significantly elevated relative to baseline (Fig 2a), despite evidence of partial  
156 resolution of specific lesions at 2 or 3 dpi versus 1 dpi (Fig S5a). There were mild-to-severe  
157 multifocal interstitial-to-alveolar patterns with soft tissue opacities (seen as ground glass  
158 opacities described in the CT scans below) in various lobes or diffusely in some animals, with  
159 more severe abnormalities in the lower lung lobes, and with the most severe findings at 3 dpi  
160 (Fig S5a). Pleural effusions were also observed.

161

162 Lung CT scans prior to infection showed a normal thorax cavity with the exception of atelectasis  
163 (Fig 2b-d, top panel). Within 1 dpi, CT scans showed increased multifocal pulmonary infiltrates  
164 with ground glass opacities in various lung lobes, linear opacities in the lung parenchyma, nodular  
165 opacities in some lung lobes, and increased soft tissue attenuation extending primarily adjacent  
166 to the vasculature (Fig 2c, Fig S5b-e). In some animals, multifocal alveolar pulmonary patterns  
167 and interstitial opacities were observed in lobe subsections, with soft tissue attenuation and focal  
168 border effacement with the pulmonary vasculature. Features intensified at 2-3 dpi, primarily in  
169 the lung periphery, but also adjacent to the primary bronchus and the vasculature (Fig 2d, Fig  
170 S5b). In other animals, progressive alveolar or interstitial pulmonary patterns were observed at  
171 2 dpi (Fig 2c). While ground glass opacities in some lobes intensified at 2 dpi relative to 1 dpi,  
172 others resolved (Fig S5c, d). In one animal, the individual nodular pattern at 1 dpi evolved to a  
173 multifocal soft tissue nodular pattern in multiple lobes with associated diffuse ground glass



174 opacities (Fig S5d). At 3 dpi, persistent, patchy, fairly diffuse ground glass pulmonary opacities  
175 existed in many lung lobes with multifocal nodular tendency (Fig S5e). Overall, CT abnormality  
176 scores continuously increased at over the 3 days relative to baseline (Fig 2e). Percent change in  
177 the hyperdensity volume was calculated using CT scans to quantify pathological changes over the  
178 course of disease <sup>8</sup>. We observed a significant increase in lung hyperdense areas between 1-3 dpi  
179 compared to the baseline scans (Fig 2f-i). Measurement of volume involved in hyperdensity  
180 showed a significant, progressive increase over time (Fig 2j). Pneumonia was evident in all  
181 infected animals relative to their baseline (Fig 2j), suggesting that while some lesions formed and  
182 resolved within the three-day infection protocol, others persisted or progressed. Together, CXR  
183 and CT scans revealed moderate multi-lobe pneumonia in infected animals, confirming the  
184 histopathology results (Fig 1h, i, Fig S2) in the very early phase of SARS-CoV-2 infection in rhesus  
185 macaques.

186  
187 We measured the levels of pro-inflammatory, Type I cytokines in the BAL fluid (Fig 3) and plasma  
188 (Fig S6a-l) of acutely infected rhesus macaques. Levels of IL-6 (Fig 3a), IFN- $\alpha$  (Fig 3b), IFN- $\gamma$  (Fig  
189 3c), IL-8 (Fig 3d), perforin (Fig 3e), IP-10 (Fig 3f), MIP1- $\alpha$  (Fig 3g) and MIP1- $\beta$  (Fig 3h) were all  
190 significantly elevated in the BAL fluid. The levels of IL-12p40 (Fig 3i), IL-18 (Fig 3j), TNF (Fig 3k)  
191 and IL-1Ra (Fig 3l) increased over time. Of particular interest was the elevation of Type I IFN- $\alpha$   
192 (Fig 3b), which has critical anti-viral activity including against SARS-CoV-2 <sup>9</sup>. Expression of a  
193 downstream Type-I interferon-regulated gene IP-10 (CXCL-10), which promotes the recruitment  
194 of CXCR3<sup>+</sup> Th1 thymocytes, was also induced (Fig 3f). Therefore, we observed that rhesus  
195 macaques mount an early anti-viral response to SARS-CoV-2 infection. Type I IFNs and IL-6 (both

196 significantly expressed) are key components of a “cytokine-storm” which promote acute  
197 respiratory distress syndrome (ARDS) associated with both SARS-CoV-1 and -2, when induced  
198 uncontrollably<sup>10</sup>. IFN- $\alpha$  and IP-10 were also significantly elevated in plasma samples at 2 and 3  
199 dpi (Fig S6).

200  
201 Thus, clinical, imaging, pathology and cytokine analyses provide evidence for an acute infection  
202 in macaques following exposure to SARS-CoV-2, which leads to a moderate pneumonia and  
203 pathology, with early activation of anti-viral responses. To study progression of infection, and  
204 assess the effect of age on SARS-CoV-2 infection, we infected six young and six old Indian-origin  
205 rhesus macaques as described above and longitudinally followed the outcome over 14-17 days  
206 (Table S1). We included four macaques as procedural controls, which were sham-infected and  
207 underwent all procedures (with the exception of necropsy) to control for the impact of multiple  
208 procedures over the course of the study (Table S1). We also infected six baboons and an equal  
209 number of marmosets with SARS-CoV-2 in order to compare the progression of COVID-19 in  
210 different NHP models.

211  
212 **Long-term study of SARS-CoV-2 infection in rhesus macaques, baboons and marmosets**  
213 **demonstrates heterogeneity in progression to COVID-19**

214 Results of the longitudinal study showed that the acute signs of SARS-CoV-2 infection and mild-  
215 to-moderate COVID-19 disease in rhesus macaques markedly improved over time (Fig S7). In  
216 general, no major differences were observed as a consequence of age, and subsequent data from  
217 young and old animals are combined (N=12), unless specified. A small subset (3/12) of animals

218 exhibited elevated serum CRP past 3 dpi (Fig S7a), although metabolic signs of dysfunction likely  
219 induced by infection (e.g. tCO<sub>2</sub> elevation) continued for the duration of the study (Fig S7b). No  
220 alterations were observed in the levels of serum albumin or hemoglobin during this timeframe  
221 (not shown). There was a significant decline in RBCs (Fig S7c) at 3 and 6 dpi which normalized or  
222 reverted by 9 dpi. The percentage of neutrophils in the peripheral blood remained unchanged  
223 between 3-14 dpi (not shown). The significant decline in blood platelets and increase in the  
224 percentage of monocytes observed at 3 dpi, were short-lived (Fig S7d, e). Despite these modest  
225 changes, the majority of animals in both age groups exhibited weight loss throughout the study  
226 duration (Fig S7f), although pyrexia was not observed (not shown).

227

228 Viral RNA was detected in BAL of 10/12 macaques at 3 dpi, but declined thereafter (Fig 4a).  
229 Detection of viral RNA was equivalent between young (5/6) and old (5/6) macaques (Fig S8a).  
230 Very low viral RNA copy numbers were detected in BAL at 9 dpi with only one young macaque  
231 testing positive, and none by 12 dpi (Fig 4a). Viral RNA appeared to persist for much longer in NS  
232 than BAL, including at study endpoint (Fig 4b). Viral RNA was detected from NS in 6/12 macaques  
233 at 3 dpi and on average young macaques harbored more virus in their nasal cavity at 3 dpi relative  
234 to old animals but the differences were not significant (Fig S8b). SARS-CoV-2 RNA was detected  
235 in 10/12 macaques (6 young, 4 old, respectively) at 9 dpi and 6/12 macaques at the end of the  
236 study period (Fig S8b). These results suggest that the virus persists for at least two weeks in the  
237 respiratory compartment of immunocompetent macaques that clinically recovered from COVID-  
238 19. Viral RNA was detected from BS in 4/12 animals at 3 and 6 dpi, but not at later time points  
239 (Fig S8c, d). No significant difference was detected between age groups. Viral RNA was also

240 detected from RS in 2/12 animals at 3, 6 and 9 dpi (Fig S8e, f). Significantly lower levels of viral  
241 RNA (2.5 logs) were detectable at the end of the study (14-17 days) when compared to viral RNA  
242 detected at the end of the 3-day protocol (Fig 4c, Fig S9a). Viral RNA was detected in the lungs of  
243 two-thirds (8/12) of all macaques and no effect of age was apparent. No viral RNA was detected  
244 in any serum samples (Fig S9b) or in randomly selected urine samples (Fig S9c). The presence of  
245 viral RNA in the lungs of macaques after two weeks following recovery from acute COVID-19  
246 indicates that while macaques control SARS-CoV-2 infection, immune responses are not  
247 sterilizing.

248  
249 Gross examination of the lungs of most infected animals at necropsy (14 to 17 dpi) was  
250 unremarkable (Fig S10a); however, red discoloration of the dorsal aspect of the lung lobes was  
251 seen in four young and two aged animals (Fig S10b). Table S3 summarizes the histopathologic  
252 findings in descending order of occurrence by anatomic location. The lungs were the most  
253 affected organ (Fig 4d, e, Table S3). Multifocal minimal to mild interstitial mononuclear  
254 inflammation was seen in 11/12 animals (Fig 4n, o, Fig S10c), generally composed of macrophages  
255 and lymphocytes that expanded the alveolar septa (Fig 4n, Fig S10d, e, f, g), with variable  
256 neutrophil infiltrates (5/12, Fig S10e), fibrosis (5/12, Fig 4o, Fig S10f, g) or vasculitis (3/12, Fig  
257 S10i). Alveolar epithelium often contained areas of type II pneumocyte hyperplasia (4/12, Fig  
258 S10e) and bronchiolization (2/12, Fig S10h). Alveolar lumina contained increased alveolar  
259 histiocytosis (9/12, Fig 4o, Fig S10d, e) occasionally admixed with neutrophils (5/12, Fig S10e).  
260 Syncytial cells (Fig S10e, f) were observed most frequently in the alveolar lumen in all 12 animals.  
261 Bronchitis was observed in 4/12, characterized by infiltrates of eosinophils within the bronchial

262 wall and epithelium (Fig S10j). Prominent perivascular lymphocytes (7/12, Fig S10k) and BALT  
263 hyperplasia (5/12, Fig S10i) were frequently observed. The majority of the animals (11/12)  
264 exhibited minimal to moderate lymphoplasmacytic and eosinophilic tracheitis.

265

266 Early detection of viral RNA in BAL was comparable between macaques and baboons (Fig 4a, f)  
267 and NS (Fig 4b, g). A third of the baboons had detectable viral RNA in NS at 12 dpi (Fig 4g), and a  
268 similar number of animals remained positive at 9 dpi in the BS (Fig S11a). The number of baboons  
269 from which viral RNA could be detected in RS increased over time from 1/6 at 3 dpi to 3/6 at 6  
270 dpi, 4/6 at 9 dpi and 3/6 at 12 dpi, underscoring long-term viral persistence of SARS-CoV-2 in  
271 baboons relative to rhesus macaques (Fig S11b). Postmortem gross examination at 14 to 17 dpi  
272 identified red discoloration of the lung lobes in all six baboons (Fig S11c, d). Table S4 summarizes  
273 the histopathologic findings in descending order of occurrence by anatomic location. Like  
274 macaques, the lungs were the most affected organ in the baboons (Fig 4h, i, Table S6, Fig S11).  
275 Multifocal minimal to moderate interstitial mononuclear inflammation was seen in 6/6 animals  
276 (Fig 4h, Fig S11f, g, h, i), generally composed of macrophages and lymphocytes that expanded  
277 the alveolar septa, with variable neutrophil infiltrates (3/6, Fig S11f, g, j, k) or fibrosis (2/6, Fig  
278 S11j, k). Alveolar epithelium often contained areas of type II pneumocyte hyperplasia (4/6, Fig 4i,  
279 Fig S11i) and bronchiolization (1/6, Fig S11l). Alveolar lumina contained increased alveolar  
280 histiocytosis (6/6, Fig 4h) occasionally admixed with neutrophils (3/6) (Fig S11f, g, h, i). Syncytial  
281 cells were observed most frequently in the alveolar lumen in all 6 animals (Fig 4h, Fig S11m).  
282 Bronchitis was observed in 6/6, characterized by infiltrates of eosinophils within the bronchial  
283 wall and epithelium (Fig S11n). BALT hyperplasia (5/6, Fig S11k) was frequently observed. The

284 majority of the animals exhibited minimal to moderate lymphoplasmacytic and eosinophilic  
285 tracheitis (5/6) and rhinitis (4/6).

286

287 SARS-CoV-2 infection was milder in marmosets. Less than 4 logs of viral RNA could be detected  
288 in NS from infected marmosets, peaking at 3 dpi, and 1/6 animals was also positive at 6 dpi. No  
289 viral RNA was detected at later time points (Fig 4j). No viral RNA was detected in BS (Fig 4k). A  
290 subset of six marmosets was euthanized at 3 dpi (n=2), while others were necropsied at 14 dpi.  
291 Approximately 2 logs of viral RNA could be detected in the lungs of marmosets at both time  
292 points. Evidence of SARS-CoV-2 infection-induced pathology, including interstitial and alveolar  
293 pneumonitis was observed in marmoset lungs as well (Fig 4m, n), although not as prevalent as in  
294 macaques or baboons. Thus, our results show that three genera of NHPs develop different  
295 degrees of COVID-19 following SARS-CoV-2 infection when evaluated side by side, with baboons  
296 exhibiting moderate to severe pathology, macaques exhibiting moderate pathology and  
297 marmosets exhibiting mild pathology. Viral RNA levels in BAL, NS and lungs are consistent with  
298 the levels of pathology. While other results also suggest that marmosets are unaffected by SARS-  
299 CoV-2 infection <sup>4</sup> (<https://www.biorxiv.org/content/10.1101/2020.03.21.001628v1>), we show  
300 that these NHPs do develop non-negligible, mild COVID-19-related pathology and some degree  
301 of viral persistence.

302

303 We performed detailed imaging of macaques in the longitudinal study. Similar to the acute study,  
304 imaging revealed the development of viral pneumonia. All macaques infected with SARS-CoV-2  
305 exhibited low baseline CXR scores (Fig 5a, Table S5) with no difference due to age (Fig 5b). Several

306 infected macaques showed changes consistent with pneumonia (Table S5) with peak severity  
307 seen between 3-6 dpi, followed by a decline by study end (Fig 5a, b, Table S5). Examples of the  
308 development of extensive pneumonia by CXR can be seen in macaques at 6 dpi, relative to  
309 baseline with subsequent resolution (Fig 5 c-e). Several animals exhibited multi-lobe alveolar  
310 infiltrates and/or interstitial opacities at 6 dpi. In other animals, there were progressive,  
311 moderate to severe interstitial and alveolar infiltrates at 6 dpi, which resolved by day 14.  
312 Conversely, the radiographs of all procedure control animals (which underwent repeated BAL  
313 procedures) exhibited normal a thorax cavity with minimal to no findings.

314  
315 High resolution CT imaging of the lungs was performed prior to and following SARS-CoV-2  
316 infection on six young and six old macaques. Pneumonia was present in all animals, post-  
317 infection, but to a significantly higher degree in old macaques relative to young (Fig 5f, Fig S12a-  
318 f, Table S6). At 6 dpi, severe patchy alveolar patterns were observed in some lobes, while other  
319 lobes had milder, interstitial patterns, with moderate to severe ground glass opacities primarily  
320 in the lungs of old macaques (Fig S12a-f). In all animals, resolution of many ground glass opacities  
321 and nodular as well as multifocal lesions was observed at 12 dpi (Fig 5f, Fig S12a, b, d-f). At 12  
322 dpi, all but one of the older macaques exhibited a normal or nearly normal thorax cavity, the  
323 latter with minimal ground glass opacities in all lung lobes studied at this time. Findings in one  
324 older macaque was considerably improved but retained patchy round glass opacities in all lobes  
325 and alveolar patterns in some lobes at 12 dpi (Fig S12c). This animal had the highest overall score  
326 by CT (Fig 5f) and CXRs (Fig 5 a-b). These results suggest that pneumonia in some older macaques  
327 may persist longer than in younger animals. Similar to the acute study, hyperdensity analysis

328 revealed a significant, progressive increase in the volume of lung involved in pneumonia at 6 dpi,  
329 which normalized by 12 dpi (Fig 5g-o).

330

331 **SARS-CoV-2 infection in macaques results in a dynamic myeloid cell response in the lungs of**  
332 **rhesus macaques**

333 Cellular composition in BAL samples and peripheral blood<sup>11,12</sup> at necropsy showed markedly  
334 altered immune cell responses in the lung compartment following infection of macaques. In  
335 healthy lungs, BAL is predominantly comprised of alveolar macrophages (AMs)<sup>13</sup> but respiratory  
336 tract infections result in the influx of other immune cells. SARS-CoV-2 infection moderately  
337 increased the proportions of myeloid cells in the BAL 3 dpi, with most returning to normal by 9  
338 dpi (Fig S13a). There was no effect of age (Fig S13b). The myeloid influx included cells phenotyped  
339 as interstitial macrophages (IMs, Fig 6a, e), neutrophils (Fig 6c, g) and plasmacytoid dendritic cells  
340 (pDCs, Fig 6d, h). In contrast, the levels of resident AMs in BAL declined significantly at 3 dpi (Fig  
341 6b, f). The increase in IMs, neutrophils and pDCs at 3 dpi was highly correlated with the levels of  
342 viral RNA (Fig 6i-j, Fig S13i), while AMs exhibited an opposite trend. The frequency of  
343 conventional dendritic cells (cDCs) declined as pDCs increased in BAL (Fig S13c). An increase in  
344 the levels of both classical (CD14<sup>+</sup>CD16<sup>-</sup>) (not shown) and intermediate/inflammatory  
345 (CD14<sup>+</sup>CD16<sup>+</sup>) monocytes in BAL was also observed at 3 dpi (Fig S13d). The frequency of myeloid  
346 subpopulations increased in BAL was generally reduced in blood (Fig S13e-h), with two  
347 exceptions - pDCs and CD14<sup>+</sup>CD16<sup>+</sup> monocytes, which were increased in the blood as well as BAL  
348 (Fig S13g-h). Relative to AMs, IMs have a shorter half-life, exhibit continuous turnover, and may  
349 help to maintain homeostasis and protect against continuous pathogen exposure from the



350 environment<sup>14</sup>. Increased recruitment of pDCs to the lungs suggests a potentially important  
351 feature of protection from advanced COVID-19 disease in the rhesus macaque model since they  
352 are a major source of anti-viral Type I interferons such as IFN- $\alpha$ , the levels of which were elevated  
353 in the BAL within 1-3 dpi (Fig 3b).

354  
355 Multi-label confocal imaging of lung tissues following Ki67 staining depicted that only few of the  
356 virally-infected cells in the lung tissue actively proliferated (Fig 5k-p). Detailed analysis of the lung  
357 tissue revealed that neutrophils (Fig 6k, l, Fig S14a, d), macrophages (Fig 6m, n, Fig S14b, h) and  
358 pDCs (Fig 6o, p, Fig S14c, i) recruited to the lung compartment (Fig 6a-h) harbored high levels of  
359 viral proteins (Fig 6k-p, Fig S14). Apart from these, many of the other cell-types contained viral  
360 proteins, suggesting a capacity of the virus to infect many cell types and that intact virus may also  
361 persist in the lungs. These novel data suggest that rapid influx of specialized subsets of myeloid  
362 cells to the lung that are known to express Type I IFNs and other pro-inflammatory cytokines is a  
363 key event in the control of SARS-CoV-2 infection.

364  
365 Infection of macaques also resulted in a significant influx of T cells to the alveolar space by 3 dpi,  
366 which normalized by 9 dpi (Fig 7a, b, g). After infection, CD4<sup>+</sup> T cells expressed significantly lower  
367 levels of antigen-experience/tissue residence (CD69; Fig 6c), Th1 (CXCR3; Fig 6d), memory (CCR7;  
368 Fig 6f), and activation (HLA-DR) (Fig 6m) markers in BAL. In contrast, the levels of CD4<sup>+</sup> T cells  
369 expressing PD-1 (Fig 6e) and LAG-3 (Fig 6n) were significantly elevated, while those of CD4<sup>+</sup> T cells  
370 expressing CCR5 (Fig 6l) were unchanged. A similar effect was observed in CD8<sup>+</sup> T cell subsets,  
371 where the expression of CD69 (Fig 6h), CXCR3 (Fig 6i), and CCR7 (Fig 6k) was significantly reduced

372 in BAL following infection whereas expression of PD-1 (Fig 6j) and LAG-3 (Fig 6q) in the CD8<sup>+</sup> T  
373 cells was significantly increased. CCR5 (Fig 6o) and HLA-DR (Fig 6p) were unchanged. No  
374 differences were observed in T cell responses in young relative to old animals. Taking data from  
375 myeloid cells and lymphocytes together, we postulate that the rapid influx of myeloid cells  
376 capable of producing high levels of Type I IFNs result in immune control of SARS-CoV-2 infection  
377 in macaques, but that this control is not sterilizing. This allows for viral antigens to persist leading  
378 T cell recruitment, but with a T cell profile associated with immune modulation and promotion  
379 of antigen-mediated T cell anergy/exhaustion (PD-1, LAG3 expression)<sup>15</sup>.

380

381 To extrapolate from phenotype to function, we explored proliferation, immune mediator  
382 production, and memory phenotypes. CD4<sup>+</sup> and CD8<sup>+</sup> T cells exhibiting proliferative (Fig 8a, g)  
383 and memory markers (Fig 8b, h) were significantly increased in BAL after infection whereas CD4<sup>+</sup>  
384 and CD8<sup>+</sup> T cells expressing naïve (Fig 8c, i) and effector (Fig 8d, j) phenotypes were significantly  
385 reduced. The percentage of CD4<sup>+</sup> (Fig 8e) and CD8<sup>+</sup> (Fig 8k) T cells expressing IL-2 was significantly  
386 elevated in the BAL at 9 dpi. A similar effect was observed for Granzyme-B (GZMB) (Fig 8f, l) which  
387 was sustained through 9 dpi. No significant effect of age was observed, although the expression  
388 of IL-2 on T cells was higher for young compared old rhesus macaques. Frequencies of CD4<sup>+</sup> and  
389 CD8<sup>+</sup> expressing interferon- $\gamma$  (IFNG) (Fig S15a, d) and IL-17 (Fig S15b, e) were elevated, but  
390 unchanged for TNF- $\alpha$  (Fig S15c, f). Greater expression of IFN $\gamma$  was measured on CD4<sup>+</sup> T cells  
391 recruited to the BAL in younger animals, but the differences were not statistically significant.  
392 These results suggest that robust cellular immune responses (both CD4<sup>+</sup> and CD8<sup>+</sup> T cells) are  
393 generated in the lung compartment (BAL) as early as day 3 and maintained at 9 dpi in many

394 instances. Following ex vivo re-stimulation of T cells from BAL at 9 dpi with CoV-specific peptide  
395 pools, CD4<sup>+</sup> T cells expressing IL-2 (Fig 8m), GZMB (Fig 8n), IFN- $\gamma$  (Fig S15g), IL-17 (Fig S15h) and  
396 TNF- $\alpha$  (Fig S15i) were not statistically elevated beyond baseline values. This was similar for CD8<sup>+</sup>  
397 T cells expressing IL-2 (Fig 8o), GZMB (Fig 8p), IFN- $\gamma$  (Fig S15j), IL-17 (Fig S15k) and TNF- $\alpha$  (Fig  
398 S15l). In combination with increased expression of the immune-regulatory markers PD-1 and  
399 LAG-3, our results suggest that T cells recruited to the lung compartment following SARS-CoV-2  
400 infection are capable of secreting cytokine but fail to generate robust antigen specific responses  
401 highlighting the fact that persistent T cell stimulation by viral antigens may generate T cell anergy  
402 relatively early in infection and this is promoted by our findings of viral persistence in the  
403 respiratory tract.

404  
405 Immunophenotyping results were confirmed by studying cytokine production in BAL and plasma  
406 (Fig S16)<sup>16</sup>. Our results show that the levels of IFN- $\alpha$  (Fig S16a), IL-1Ra (Fig S16b), and IL-6 (Fig  
407 S16d) were elevated in BAL following infection, but levels rapidly normalized after the 3 dpi peak.  
408 Levels of IFN- $\alpha$  were also induced in plasma (Fig S16g), but not those of IL-1Ra (Fig S16h), and IL-  
409 6 (Fig S16j) or other cytokines studied. Cytokines were not induced at baseline or in procedure  
410 control animals. Overall, the longitudinal study results were consistent with the acute infection  
411 study in the expression of Type I pro-inflammatory cytokines responsible for viral control (IFN- $\alpha$ )  
412 and expression of IL-6, which may contribute to a cytokine storm and development of ARDS in a  
413 subset of hosts during COVID-19.

414

415 Protein levels of ACE-2, one presumed receptor for SARS-CoV-2 in humans, were detected at  
416 higher levels in the lungs and nasal epithelia of infected macaques than those in the lungs of  
417 naive rhesus macaques (Fig 1j, k). Using RNAseq we also studied if expression of ACE-2 could be  
418 detected in macaque lung tissues and elevated in SARS-CoV-2 infected animals. This was  
419 indeed the case (Fig S17a-d) in a statistically significant manner two weeks after infection despite  
420 multiple hypothesis correction (Fig S17a, b). Interestingly, ACE-2 expression was significantly  
421 higher in young compared to old macaques (Fig S17c, d). These results potentially explain the  
422 higher levels of virus that we observed in several samples derived from young macaques in these  
423 two cohorts (Fig S8). Expression of transcripts specific for other viral receptors/co-receptors e.g.,  
424 Cathepsin-L, CD147 or TMPRSS2 was not significantly altered in the lung two weeks after  
425 infection (Fig S17a).

426  
427 Altogether, our results show that rhesus macaques, baboons and marmosets can all be infected  
428 with SARS-CoV-2 but exhibit differential progression to COVID-19. While marmosets exhibit mild  
429 infection, macaques are characterized by the presence of moderate progressive pneumonia that  
430 is rapidly resolved. This is accompanied by a marked reduction in lung and nasal viral loads.  
431 Baboons appear to have the most lung pathology, and the level of viral shedding and persistence  
432 in extra-respiratory compartment is also greater in this model. Furthermore, we show the  
433 importance of state-of-the-art, non-invasive imaging – cone beam CT scanning, and the  
434 application of innovative algorithms to identify the extent of lung involved in pneumonia, in  
435 developing models of COVID-19. This provided us with a quantifiable metric that lent itself to  
436 accurately assessing the efficacy of vaccines or the impact of therapeutic interventions.

437

438 Our results also point out, for the first time, that SARS-CoV-2 infection is associated with dynamic  
439 influxes of specific subsets of myeloid cells to the lung, particularly IMs, neutrophils and pDCs,  
440 and that viral proteins can be detected in these cells. These cellular influxes are likely due to a  
441 strong viral-induced myelopoiesis. This may help explain both development of COVID-19  
442 pneumonia and subsequent control via expression of a strong Type I IFN response and expression  
443 of other pro-inflammatory cytokines. We speculate that these responses clear the majority of  
444 virus, and, in doing so, lead to eventual resolution of pneumonia, while limiting a progressive  
445 cytokine storm and ARDS in the majority of hosts. Macaques have served as excellent models of  
446 infectious diseases and vaccine development efforts<sup>17-19</sup>, and this model permits lung imaging  
447 and detailed immune evaluations. Given the ability to reproducibly measure viral loads in NS and  
448 BAL, and quantify lung involvement by CT scans and hyperdensity analyses, we expect this model  
449 to play a critical role in the preclinical testing of novel candidate vaccines against SARS-CoV-2  
450 infection and/or COVID-19 disease in development. Experiments in rhesus macaques can also  
451 evaluate safety and immunogenicity, including the important issue of antibody-mediated  
452 immune enhancement. Since mild-to-moderate COVID-19 disease that follows SARS-CoV-2  
453 infection in rhesus macaques is short-lived, it follows that vaccine safety and efficacy studies can  
454 be evaluated in short term studies.

455

456 However, detection of both virus and its protein antigens over two weeks in macaques, baboons  
457 and even marmosets, indicates viral persistence rather than sterilizing immunity. Support for this  
458 comes from the finding of PD-1 and LAG-3 expression by CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the lung and

459 lack of induction of antigen-specific immune effector cytokine production by these cells.  
460 Characterization of these responses is particularly important considering that T cell responses,  
461 particularly T helper responses, play key roles in shaping the nature of downstream B cell  
462 responses and production of antibodies. It is likely that in immunocompromised patients,  
463 persistent presence of SARS-CoV-2 could lead to exacerbated disease. Since COVID-19 has  
464 disproportionately affected the aging human population, we included age as an independent  
465 variable in our studies. Although there were several smaller changes observed in older animals,  
466 old and young animals both resolved infection. While it is possible that NHPs do not completely  
467 model all aspects of COVID-19 in humans, these findings suggest that underlying conditions which  
468 impact immunity such as defined and undefined co-morbidities, rather than aging per se, may be  
469 responsible for the greater morbidity and mortality observed due to COVID-19 in the aged human  
470 population (and a subset of younger individuals). Baboons developed more extensive disease and  
471 pathology with more widespread and severe inflammatory lesions compared to rhesus  
472 macaques. Baboons are also a preferred model of cardiovascular and metabolic diseases  
473 including diabetes<sup>20-22</sup>, and therefore further development of the baboon model may prove  
474 especially useful for the study of co-morbidities with COVID-19 such as diabetes, cardiovascular  
475 disease, and aging.

476

## 477 **Methods**

478

479 **Study approval.** All of the infected animals were housed in Animal Biosafety Level 3 or 4 (ABSL3,  
480 ABSL4) at the Southwest National Primate Research Center where they were treated per the

481 standards recommended by AAALAC International and the NIH Guide for the Care and Use of  
482 Laboratory Animals. Sham controls were housed in ABSL2. The animal studies in each of the  
483 species were approved by the Animal Care and Use Committee of the Texas Biomedical Research  
484 Institute and as an omnibus Biosafety Committee protocol.

485

486 **Animal studies and clinical evaluations.** 16 (eight young and eight young, see Table S1 for details)  
487 Indian-origin rhesus macaques (*Macaca mulatta*), and six African-origin baboons (*Papio*  
488 *hamadryas*) all from SNPRC breeding colonies, were exposed via multiple routes (ocular, 100  $\mu$ L;  
489 intranasal, 200  $\mu$ L - using a Teleflex Intranasal Mucosal Atomization Device; intratracheal, 200  $\mu$ L  
490 - using a Teleflex Laryngo-Tracheal Mucosal Atomization Device) of inoculation to 500  $\mu$ L of an  
491 undiluted stock of SARS-CoV-2, which had a titer of 2.1E+06 pfu/mL, resulting in the  
492 administration of 1.05x10<sup>6</sup> pfu SARS-CoV-2. SARS-CoV-2 generated from isolate USA-WA1/2020  
493 was used for animal exposures. A fourth cell-culture passage (P4) of SARS-CoV-2 was obtained  
494 from Biodefense and Emerging Infections Research Resources Repository (BEI Resources, catalog  
495 number NR-52281, GenBank accession number MN985325.1) and propagated at Texas Biomed.  
496 The stock virus was passaged for a fifth time in Vero E6 cells at a multiplicity of infection (MOI)  
497 of approximately 0.001. This master stock was used to generate a sixth cell culture passage  
498 exposure stock by infecting VeroE6 cells at a MOI of 0.02. The resulting stock had a titer of 2.10  
499 x 10<sup>6</sup> PFU/mL and was attributed the Lot No. 20200320. The exposure stock has been confirmed  
500 to be SARS-CoV-2 by deep sequencing and was identical to published sequence (MN985325).  
501 strain USA-WA1/2020 (BEI Resources, NR-52281, Manassas, VA). Six Brazilian-origin common  
502 marmosets (*Callithrix jacchus*) were also infected via the combined routes (80 $\mu$ L intranasal; 40 $\mu$ L

503 ocular [20µL/eye]; 40µL oral performed twice for a total of 160µL intranasal, 80µL ocular; 80µL  
504 oral and 100µL IT) of the same stock. The total target dose presented to marmosets was 8.82E+05  
505 pfu/mL. Four macaques, baboons and marmosets each were sham-infected with DMEM-10  
506 media (the storage vehicle of the virus), to be used as procedural controls. Infected animals were  
507 euthanized for tissue collection at necropsy, and control animals were returned to the colony.  
508 Macaques were enrolled from a specific pathogen-free colony maintained at the SNPRC and were  
509 tested free from SPF-4 (simian retrovirus D, SIV, STLV-1 and herpes B virus). All animals including  
510 the baboons and the marmosets were also free of *Mycobacterium tuberculosis*. Animals were  
511 monitored regularly by a board-certified veterinary clinician for rectal body temperature, weight  
512 and physical examination. Collection of blood, BAL, nasal swab, and urine, under tiletamine-  
513 zolazepam (Telazol) anesthesia was performed as described (Table S1), except that BAL was not  
514 performed in marmosets. Four macaques were sampled daily until euthanized at 3dpi. All other  
515 macaques and all the baboons were sampled at 0, 3, 6, 9, 12 dpi and at euthanasia (BAL  
516 performed weekly). Blood was collected for complete blood cell analysis and specialized serum  
517 chemistries. Animals were observed daily to record alert clinical measurements. Nasal  
518 (longitudinal) or nasopharyngeal (acute) swabs and BALs were obtained to measure viral loads in  
519 a longitudinal manner, as described earlier <sup>11</sup>. Briefly, in a sitting position, the larynx was  
520 visualized and a sterile feeding tube inserted into the trachea and advanced until met with  
521 resistance. Up to 80ml of warm sterile saline was instilled, divided into multiple aliquots. Fluid  
522 was aspirated and collected for analysis.

523 **Chest X-Rays.** Clinical radiographic evaluation was performed as following: The lungs of all  
524 animals were imaged by conventional (chest radiography, CXR), as previously described <sup>23</sup>. Three



525 view thoracic radiographs (ventrodorsal, right and left lateral) were performed at all sampling  
526 time points. High-resolution computed tomography (CT) was performed daily through 3 dpi in 4  
527 infected macaques and on 6 and 12 dpi in 3 young and 3 old macaques as described in the next  
528 section. Images were evaluated by a board-certified veterinary radiologist and scored as normal,  
529 mild moderate or severe disease. The changes were characterized as to location (lung lobe) and  
530 distribution (perivascular/peribronchial, hilar, peripheral, diffuse, multifocal/patchy).

531 **CT Imaging and quantitative analysis of lung pathology.** The animals were anesthetized using  
532 Telazol (2-6mg/kg) and maintained by inhaled isoflurane delivered through Hallowell 2002  
533 ventilator anesthesia system (Hallowell, Pittsfield, MA). Animals were intubated to perform end-  
534 inspiratory breath-hold using a remote breath-hold switch. Lung field CT images were acquired  
535 using Multiscan LFER150 PET/CT (MEDISO Inc., Budapest, Hungary) scanner. Image analysis was  
536 performed using 3D ROI tools available in Vivoquant (Invicro, Boston, MA). Percent change in  
537 lung hyperdensity was calculated to quantify lung pathology (1, 2). The lung volume involved in  
538 pneumonia, was quantified as follows: briefly, lung segmentation was performed using a  
539 connected thresholding feature, to identify lung ROI by classifying all the input voxels of scan in  
540 the range of -850 HU to -500 HU. Smoothing filters were used to reassign every ROI voxel value  
541 to the mode of the surrounding region with defined voxel radius and iterations to reconstruct  
542 the Lung ROI. Thereafter, global thresholding was applied to classify the voxels within Lung ROI  
543 in the range of -490 HU to +500 HU to obtain Lung hyperdensity ROI. The resultant ROIs were  
544 then rendered in the maximum intensity projection view using the VTK feature.

545

546 **Viral RNA determination.** Viral RNA from plasma/sera, BAL, urine, saliva, and swabs  
547 (nasal/nasopharyngeal, oropharyngeal, rectal) and lung homogenates was determined by RT-  
548 qPCR and viral RNA isolation as previously described for MERS-CoV and SARS-CoV (12, 27, 28).  
549 RNA extraction from fluids was performed using the EpMotion M5073c Liquid Handler  
550 (Eppendorf) and the NucleoMag Pathogen kit (Macherey-Nagel). 100  $\mu$ L of test sample were  
551 mixed with 150  $\mu$ L of 1X DPBS (Gibco) and 750  $\mu$ L TRIzol LS. Inactivation controls were prepared  
552 with each batch of samples to ensure no cross contamination occurred during inactivation.  
553 Samples were thawed at room temperature and then, for serum, swabs and urine samples 10 $\mu$ g  
554 yeast tRNA was added, along with 1 x 10<sup>3</sup> pfu of MS2 phage (*Escherichia coli* bacteriophage MS2,  
555 ATCC). DNA LoBind Tubes (Eppendorf) were prepared with 20  $\mu$ L of NucleoMag B-Beads  
556 (NucleoMag Pathogen kit, Macherey-Nagel) and 975  $\mu$ L of Buffer NPB2 (NucleoMag Pathogen kit,  
557 Macherey-Nagel). After centrifugation, the upper aqueous phase of each sample was transferred  
558 to the corresponding new tube containing NucleoMag B-Beads and Buffer NPB2. The samples  
559 were mixed using HulaMixer (Thermo Fisher Scientific Inc.) rotating for 10 min at room  
560 temperature. Samples were then transferred to the sample rack on EpMotion M5073c Liquid  
561 Handler (Eppendorf) for further processing according to NucleoMag Pathogen kit instructions.  
562 For viral RNA determination from tissues, 100mg of tissue was homogenized in 1mL Trizol  
563 Reagent (Invitrogen, Grand Island, NY, USA) with a Qiagen (Germantown, MD, USA) steel bead  
564 and Qiagen Stratagene TissueLyser. For detection of infectious virus, briefly, tissues were  
565 homogenized 10% w/v in viral transport medium using Polytron PT2100 tissue grinders  
566 (Kinematica). After low-speed centrifugation, the homogenates were frozen at  $-70^{\circ}$ C until they  
567 were inoculated on Vero E6 cell cultures in 10-fold serial dilutions. The SARS-CoV-2 RT-qPCR was

568 performed using a CDC-developed 2019-nCoV\_N1 assay with the TaqPath™ 1-Step RT-qPCR  
569 Master Mix, CG (ThermoFisher). The assays were performed on a QuantStudio 3 instrument  
570 (Applied Biosystems) with the following cycling parameters: Hold stage 2 min at 25°C, 15 min at  
571 50°C, 2 min at 95°C. PCR stage 45 cycles of 3 s at 95°C, 30 s at 60°C. Primer and probe info: 2019-  
572 nCoV\_N1-F: GACCCCAAATCAGCGAAAT (500nM); 2019-nCoV\_N1-R:  
573 TCTGGTTACTGCCAGTTGAATCTG (500 nM); 2019-nCoV\_N1-P FAM/MGB probe:  
574 ACCCCGCATTACGTTTGGTGGACC (125nM).

575

576 **Pathology.** Animals were euthanized and complete necropsy was performed. Gross images (lung,  
577 spleen, liver) and organ weights (lymph nodes, tonsil, spleen, lung, liver, adrenal glands) were  
578 obtained at necropsy. Representative samples of lung lymph nodes (inguinal, axillary, mandibular  
579 and mediastinal), tonsil, thyroid gland, trachea, heart, spleen, liver, kidney, adrenal gland,  
580 digestive system (stomach, duodenum, jejunum, ileum, colon, and rectum), testes or ovary,  
581 brain, eye, nasal tissue, and skin were collected for all animals. Tissues were fixed in 10% neutral  
582 buffered formalin, processed to paraffin, sectioned at 5 um thickness, stained with hematoxylin  
583 and eosin utilizing standard methods, and evaluated by a board-certified veterinary pathologist.

584

585 **Tissue processing, flow cytometry, multiplex cytokine analyses, immunohistochemistry,**  
586 **multicolor confocal microscopy and RNAseq for immune evaluations.**

587 Flow cytometry was performed as previously described<sup>24-26</sup> on blood and BAL samples collected  
588 on time points days 3, 6, 9, 12, and at endpoint, which occurred at 14-17 dpi for various animals.  
589 A comprehensive list of antibodies used in these experiments is provided in Table S7. For

590 evaluations on peripheral blood, PBMC were prepared as previously described. Briefly, Cellular  
591 phenotypes were studied using antibodies: CD3 (clone SP34-2), CD4 (clone L200), CD69 (clone  
592 FN50), CD20 (2H7), CD95 (clone DX2), KI67 (B56), CCR5 (3A9), CCR7(clone 3D12), CD28 (clone  
593 CD28.2), CD45 (clone D058-1283), CXCR3 (clone 1C6/CXCR3), HLA-DR (clone L243), CCR6 (clone  
594 11A9), LAG-3 (Polyclonal, R&D Systems, Minneapolis, MN, USA), CD123 (clone 7G3), CD14 (clone  
595 M5E2), CD206 (clone 206), CD16 (clone 3G8), CD163 (GHI/61), CD66abce (Clone TET2, Miltenyi  
596 Biotech, USA), CD40 (clone 5C3), IL-2(clone MQ1-17H12) , Granzyme-B (clone GB11) all  
597 purchased from BD Biosciences (San Jose, CA, USA) unless specified. CD8 (clone RPA-T8), CD11c  
598 (clone 3.9), TNF-alpha (clone MAb11), IFN-gamma (clone B27), IL-17 (clone BL168) and PD-1  
599 (clone EH12.2H7) were purchased from BioLegend, San Diego, CA, US. For antigenic stimulation  
600 cells were cultured overnight with SARS-CoV-2 specific peptide pools of the nucleocapsid (N),  
601 membrane (M) and spike (S) proteins (PepTivator SARS-CoV-2 peptide pool, Miltenyi Biotech,  
602 USA). A detailed gating strategy for detection and enumeration of various cellular phenotypes is  
603 described (Fig S18).

604  
605 Immuno-histochemistry was performed on 4 µm thick sections of lung, nasal cavity and tonsils.  
606 The sections were baked at 65°C for 30 min followed by de-paraffinization using Xylene and  
607 subsequent hydration with decreasing gradations of ethanol as described <sup>11,27</sup>. Heat induced  
608 antigen retrieval was performed using Sodium citrate buffer (10mM, pH 6.0) followed by blocking  
609 (3 % BSA in TBST for 1 h at 37°C). For SARS CoV-2 detection, specimens were incubated with  
610 rabbit SARS CoV-2 spike (S) antibody (ProSci, USA, 1:200, 37°C for 2 h) or anti-SARS CoV-2  
611 nucleocapsid (N) antibody (Sino Biologicals, USA, 1:100, 2h at 37°C). Antihuman ACE-2 (R&D  
612 Systems, USA, 1:50, 2h at 37°C) was used for identification of ACE-2. Mouse anti-human

613 CD66abce-PE conjugated (Miltenyi Biotech, USA, 1:20, 2 h at 37<sup>0</sup>C) was used for identification of  
614 neutrophils; mouse CD68 (Thermo Fisher Scientific, USA, 1:100, 2 h at 37<sup>0</sup>C) for macrophages and  
615 pDC's were identified by co-staining of PE conjugated mouse anti-human CD123 (BD Biosciences,  
616 USA, 1:20, 37<sup>0</sup>C for 2h) and mouse anti-human HLA-DR antibody (Thermo Fisher Scientific, USA,  
617 1:100, 2 h at 37<sup>0</sup>C). Also, mouse anti-Ki67 (BD Biosciences, USA, 1:50, 2 h at 37<sup>0</sup>C) was used for  
618 detection of actively proliferating cells. Chicken anti-rabbit IgG (H+L), Alexa Fluor 488 conjugate;  
619 goat anti-mouse IgG (H+L), Alexa Fluor 647 conjugate; donkey anti-mouse IgG (H+L), Alexa-Fluor  
620 555 conjugate secondary antibodies (Thermo Fisher Scientific, USA, 1:400, 1 h at 37<sup>0</sup>C) were used  
621 for labelling Spike, Ki67 and HLA-DR, CD68 primary antibodies respectively. Tissue sections were  
622 then stained with DAPI (Thermo Fisher Scientific, USA, 1:5000, 5 min at 37<sup>0</sup>C) with subsequent  
623 mounting with Prolong Diamond Antifade mountant (Thermo Fisher Scientific, USA). Zeiss LSM  
624 800 confocal microscope was used to visualize the stained sections (10X, 20X and 63X  
625 magnification).

626  
627 RNA was isolated, RNAseq performed and data analyzed as described <sup>16</sup>.

628  
629  
630 **Statistical analyses. Statistical analyses.** Graphs were prepared and statistical comparisons  
631 applied using GraphPad Prism version 8 (La Jolla, CA). Various statistical comparisons were  
632 performed viz. 2-tailed Student's t-test, ordinary analysis of variance (ANOVA) or one-way or two-  
633 way repeated measure analysis of variance (rmANOVA) with Geisser-Greenhouse correction for  
634 sphericity and Tukey's post hoc correction for multiple-testing (GraphPad Prism 8) was applied  
635 wherever applicable and as described in the figure legends. For Correlation analysis, Spearman's

636 rank test was applied. Statistical differences between groups were reported significant when the  
637 p-value is less than or equal to 0.05. The data are presented in mean  $\pm$  SEM.

638

639 **Author Contributions.** DK, LSS, RC, LDG designed these studies. DKS, SRG, BS, JC, KJA, RE, T-HL,  
640 MG, YG-G, RS, AC, RT, MG, CA, AB, JF, CB, HS, LP, JC, AM, BK, RNP, PE, VH, XA, AB, CK, MA, BR  
641 conducted the experiments and acquired the data. EC, AG, JD, SH-U, PAF, CNR, KS, CC, CH, OG,  
642 JD, AKV, CH, EJD and KB provided veterinary, veterinary pathology, imaging, colony management  
643 or management expertise; DKS, SRG, BS, KJA, AC, MG, EC, RNP, JS, AO, DKA, RC, BR, TJCA, SAK,  
644 MM, LDG, RC and DK analyzed the data; DK wrote the paper; LSS, JT, LDG, RC, JBT, KB, EC, LMS,  
645 JLP, SG and DKS provided assistance with writing the paper.

646

647 **Acknowledgments.** We acknowledge exceptional work by our SNPRC veterinary technical and  
648 care staff (especially the veterinary technical/animal care groups headed by Tyneshia Camp,  
649 Wade Hodgkins, Manuel Aguilar, David Vandenberg and Laura Rumpf) as well as the entire SNPRC  
650 and Texas Biomed administrative staff, especially Helen Hawn, for assistance with this study,  
651 especially during trying times.

652

653 **Statement on conflict of interests:** “RC, Jr is funded by Regeneron, Inc. This funder had no role,  
654 however, in the design and execution of the experiments and the interpretation of data. The  
655 authors declare that no other financial conflict of interest exists.”

656

657 **Financial support.** This work was primarily supported by a philanthropic award to Texas Biomed  
658 Coronavirus Working Group; a SNPRC Pilot study award to LDG, RC, JP, LM and JBT; an award to  
659 RC, Jr from Regeneron Pharmaceuticals, (contract # 2020\_004110) in part with federal funds from  
660 the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness  
661 and Response; Biomedical Advanced Research and Development Authority, under Contract No.  
662 HHSO100201700020C; and institutional NIH awards P51OD111033 and U42OD010442. The  
663 views expressed here are those of the authors and do not necessarily represent the views or  
664 official position of the funding agencies.

665

## 666 **References**

- 667 1 Callaway, E., Cyranoski, D., Mallapaty, S., Stoye, E. & Tollefson, J. The coronavirus  
668 pandemic in five powerful charts. *Nature* **579**, 482-483, doi:10.1038/d41586-020-00758-  
669 2 (2020).
- 670 2 Bucsan, A. N., Mehra, S., Khader, S. A. & Kaushal, D. The current state of animal models  
671 and genomic approaches towards identifying and validating molecular determinants of  
672 Mycobacterium tuberculosis infection and tuberculosis disease. *Pathog Dis* **77**,  
673 doi:10.1093/femspd/ftz037 (2019).
- 674 3 Gretebeck, L. M. & Subbarao, K. Animal models for SARS and MERS coronaviruses. *Curr*  
675 *Opin Virol* **13**, 123-129, doi:10.1016/j.coviro.2015.06.009 (2015).
- 676 4 Rockx, B. *et al.* Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman  
677 primate model. *Science*, doi:10.1126/science.abb7314 (2020).
- 678 5 Munster, V. J. *et al.* Respiratory disease in rhesus macaques inoculated with SARS-CoV-2.  
679 *Nature*, doi:10.1038/s41586-020-2324-7 (2020).
- 680 6 Yu, J. *et al.* DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science*,  
681 doi:10.1126/science.abc6284 (2020).
- 682 7 Chandrashekar, A. *et al.* SARS-CoV-2 infection protects against rechallenge in rhesus  
683 macaques. *Science*, doi:10.1126/science.abc4776 (2020).
- 684 8 Cockrell, A. S. *et al.* A spike-modified Middle East respiratory syndrome coronavirus  
685 (MERS-CoV) infectious clone elicits mild respiratory disease in infected rhesus macaques.  
686 *Sci Rep* **8**, 10727, doi:10.1038/s41598-018-28900-1 (2018).
- 687 9 Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S. & Huang, C. Antiviral activities of  
688 type I interferons to SARS-CoV-2 infection. *Antiviral Res* **179**, 104811,  
689 doi:10.1016/j.antiviral.2020.104811 (2020).

- 690 10 Nile, S. H. *et al.* COVID-19: Pathogenesis, cytokine storm and therapeutic potential of  
691 interferons. *Cytokine Growth Factor Rev*, doi:10.1016/j.cytogfr.2020.05.002 (2020).
- 692 11 Bucsan, A. N. *et al.* Mechanisms of reactivation of latent tuberculosis infection due to SIV  
693 co-infection. *J Clin Invest*, doi:10.1172/JCI125810 (2019).
- 694 12 Gautam, U. S. *et al.* In vivo inhibition of tryptophan catabolism reorganizes the  
695 tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis.  
696 *Proc Natl Acad Sci U S A* **115**, E62-E71, doi:10.1073/pnas.1711373114 (2018).
- 697 13 Cai, Y. *et al.* In vivo characterization of alveolar and interstitial lung macrophages in rhesus  
698 macaques: implications for understanding lung disease in humans. *J Immunol* **192**, 2821-  
699 2829, doi:10.4049/jimmunol.1302269 (2014).
- 700 14 Kuroda, M. J. *et al.* High Turnover of Tissue Macrophages Contributes to Tuberculosis  
701 Reactivation in Simian Immunodeficiency Virus-Infected Rhesus Macaques. *J Infect Dis*,  
702 doi:10.1093/infdis/jix625 (2018).
- 703 15 Barber, D. L. *et al.* Restoring function in exhausted CD8 T cells during chronic viral  
704 infection. *Nature* **439**, 682-687, doi:10.1038/nature04444 (2006).
- 705 16 Ahmed, M. *et al.* Immune correlates of tuberculosis disease and risk translate across  
706 species. *Sci Transl Med* **12**, doi:10.1126/scitranslmed.aay0233 (2020).
- 707 17 Darrah, P. A. *et al.* Prevention of tuberculosis in macaques after intravenous BCG  
708 immunization. *Nature* **577**, 95-102, doi:10.1038/s41586-019-1817-8 (2020).
- 709 18 Veazey, R. S. *et al.* Gastrointestinal tract as a major site of CD4+ T cell depletion and viral  
710 replication in SIV infection. *Science* **280**, 427-431 (1998).
- 711 19 Barouch, D. H., Klasse, P. J., Dufour, J., Veazey, R. S. & Moore, J. P. Macaque studies of  
712 vaccine and microbicide combinations for preventing HIV-1 sexual transmission. *Proc Natl*  
713 *Acad Sci U S A* **109**, 8694-8698, doi:10.1073/pnas.1203183109 (2012).
- 714 20 Cox, L. A. *et al.* Nonhuman Primates and Translational Research-Cardiovascular Disease.  
715 *ILAR J* **58**, 235-250, doi:10.1093/ilar/ilx025 (2017).
- 716 21 Rincon-Choles, H. *et al.* Renal histopathology of a baboon model with type 2 diabetes.  
717 *Toxicol Pathol* **40**, 1020-1030, doi:10.1177/0192623312444025 (2012).
- 718 22 Cole, S. A., Laviada-Molina, H. A., Serres-Perales, J. M., Rodriguez-Ayala, E. &  
719 Bastarrachea, R. A. The COVID-19 Pandemic during the Time of the Diabetes Pandemic:  
720 Likely Fraternal Twins? *Pathogens* **9**, doi:10.3390/pathogens9050389 (2020).
- 721 23 Kaushal, D. *et al.* Mucosal vaccination with attenuated Mycobacterium tuberculosis  
722 induces strong central memory responses and protects against tuberculosis. *Nat Commun*  
723 **6**, 8533, doi:10.1038/ncomms9533 (2015).
- 724 24 Bucsan, A. N. *et al.* Mechanisms of reactivation of latent tuberculosis infection due to SIV  
725 coinfection. *J Clin Invest* **129**, 5254-5260, doi:10.1172/JCI125810 (2019).
- 726 25 Foreman, T. W. *et al.* Isoniazid and Rifapentine Treatment Eradicates Persistent  
727 Mycobacterium tuberculosis in Macaques. *Am J Respir Crit Care Med*,  
728 doi:10.1164/rccm.201903-0646OC (2019).
- 729 26 Foreman, T. W. *et al.* CD4+ T-cell-independent mechanisms suppress reactivation of  
730 latent tuberculosis in a macaque model of HIV coinfection. *Proc Natl Acad Sci U S A* **113**,  
731 E5636-5644, doi:10.1073/pnas.1611987113 (2016).



- 732 27 Mehra, S. *et al.* Granuloma correlates of protection against tuberculosis and mechanisms  
733 of immune modulation by *Mycobacterium tuberculosis*. *J Infect Dis* **207**, 1115-1127,  
734 doi:10.1093/infdis/jis778 (2013).
- 735 28 Joosten, S. A. *et al.* *Mycobacterium tuberculosis* peptides presented by HLA-E molecules  
736 are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. *PLoS Pathog*  
737 **6**, e1000782, doi:10.1371/journal.ppat.1000782 (2010).
- 738 29 Raju, R. M. *et al.* Post-translational regulation via Clp protease is critical for survival of  
739 *Mycobacterium tuberculosis*. *PLoS Pathog* **10**, e1003994,  
740 doi:10.1371/journal.ppat.1003994 (2014).
- 741 30 Winglee, K. *et al.* Aerosol *Mycobacterium tuberculosis* infection causes rapid loss of  
742 diversity in gut microbiota. *PLoS One* **9**, e97048, doi:10.1371/journal.pone.0097048  
743 (2014).  
744

745

746

747

748

749

750

751

752

753

754

755

756

757

758


759

760 **Figure legends**

761

762 **Figure 1. Clinical correlates of SARS-CoV-2 infection in rhesus macaques over 0-3 dpi.** Changes  
763 in serum CRP (mg/L) (a), albumin (ALB) (g/dL) (b), hemoglobin (HGB) content (g/dL) (c),  
764 longitudinally in peripheral blood. Viral RNA ( $\log_{10}$  copies/mL) were measured by RT-PCR in BAL  
765 fluid (d), nasopharyngeal (e), and buccopharyngeal (f) swabs longitudinally (red – 0 dpi; purple –  
766 1 dpi; blue – 2 dpi; green – 3 dpi). Viral RNA was also measured in lung tissue homogenates at  
767 endpoint (3 dpi) and data is expressed as  $\log_{10}$  copies/gram of the lung tissue for random samples  
768 from three lobes in left (orange) and right (teal) lungs (g Hematoxylin and eosin (H&E) staining  
769 was performed on formalin-fixed paraffin-embedded (FFPE) lung sections from infected animals  
770 for pathological analysis. Histopathologic analysis revealed bronchitis characterized by infiltrates  
771 of macrophages, lymphocytes, neutrophils, and eosinophils that expanded the wall (bracket),  
772 and along with syncytial cells (arrows) filled the bronchiole lumen and adjacent alveolar spaces.  
773 (h); Suppurative interstitial pneumonia with Type II pneumocyte hyperplasia (arrowheads) and  
774 alveolar space filled with neutrophils, macrophages and fibrin (\*). Bracket denotes alveolar  
775 space. (i). Multilabel confocal immunofluorescence microscopy of lungs (j) and nasal epithelium  
776 (k) at 63x with Nucleocapsid (N) specific antibody (green) DAPI (blue), and ACE2 (red). (a-f) Data  
777 is represented as mean  $\pm$  SEM (n=4). (c-g) Undetectable results are represented as 1 copy. One  
778 way Repeated-measures ANOVA with Geisser-Greenhouse correction for sphericity and Tukey's  
779 post hoc correction for multiple-testing (GraphPad Prism 8) was applied. \* P<0.005, \*\* P<0.005,  
780 \*\*\* P<0.0005.

781



783 **Figure 2. Radiologic evaluation of the lung compartment following SARS-CoV-2 infection in**  
784 **rhesus macaques over 0-3 dpi including by hyperdensity analyses.** CXR (a) and CT (e) scores  
785 generated by a veterinary radiologist blinded to the experimental group (red – 0 dpi; purple – 1  
786 dpi; blue – 2 dpi; green – 3 dpi). (a) Data is represented as mean $\pm$  SEM (n=4). One way Repeated-  
787 measures ANOVA with Geisser-Greenhouse correction for sphericity and Tukey's post hoc  
788 correction for multiple-testing (GraphPad Prism 8) was applied. \* P<0.05. Representative CT scan  
789 images performed on Day 0-2 dpi show (b) transverse, (c) vertical, (d) longitudinal view of left  
790 caudal lobe ground glass opacity on 1 dpi (middle), 2 dpi<sup>28</sup> and baseline at 0 dpi (upper inset). CT  
791 scans (b-d) revealed evidence of pneumonia and lung abnormalities in the infected animals  
792 relative to controls which resolved between 1 to 2 dpi (red arrow). 3D reconstruction (f) of ROI  
793 volume representing the location of lesion. (Fig 2g-i) represent image for quantification of lung  
794 lesion with green area representing normal intensity lung voxels (-850 HU to -500 HU), while red  
795 areas represent hyperdense voxels (-490 HU to 500 HU). Percent change in lung hyperdensity in  
796 SARS-CoV2 infected animals over Day 1-3 dpi compared to the baseline(j). (red – 0 dpi; purple –  
797 1 dpi; blue – 2 dpi; green – 3 dpi). (e, j) Data represented as (mean  $\pm$  SEM) (n=4 for 0-2 dpi, n=2  
798 for 3dpi). Ordinary one-way ANOVA with Dunnett's post hoc test was applied.

799

800


801

802

803

804

**Fig 2**



806 **Figure 3. SARS-CoV-2 induced alveolar inflammation.** Simultaneous analysis of multiple  
807 cytokines by Luminex technology in the BAL fluid of rhesus macaques over 0-3 dpi. Levels of IL-6  
808 (a), IFN-a (b), IFN-g (c), IL-8 (d), perforin (e), IP-10 (f), MIP1a (g), MIP1b (h), IL-12p40 (i), IL-18 (j),  
809 TNF (k) and IL-1Ra (l) are expressed in Log10 concentration in picogram per mL of BAL fluid. (red  
810 – 0 dpi; purple – 1 dpi; blue – 2 dpi; green – 3 dpi). Data is represented as mean $\pm$  SEM (n=4). One  
811 way Repeated-measures ANOVA with Geisser-Greenhouse correction for sphericity and Tukey's  
812 post hoc correction for multiple-testing (GraphPad Prism 8) was applied. \* P<0.005, \*\* P<0.005,  
813 \*\*\* P<0.0005.

814

815

816

817

818

819

820

821

822


823

824

825

826

827



829 **Figure 4. Longitudinal clinical and histopathological correlates of SARS-CoV-2 infection in**  
830 **rhesus macaques, baboons and marmosets over two weeks.** Viral RNA ( $\log_{10}$  copies/mL were  
831 measured by RT-PCR in BAL fluid (a) and nasopharyngeal (b) swabs of SARS-CoV-2 infected rhesus  
832 macaques longitudinally (red – 0 dpi; purple – 3 dpi; black – 6 dpi; blue – 9 dpi; orange – 12 dpi;  
833 green – 14-17 dpi). (n=12) One way Repeated-measures ANOVA with Geisser-Greenhouse  
834 correction for sphericity and Tukey's post hoc correction for multiple-testing (GraphPad Prism 8)  
835 was applied. \*  $P < 0.005$ , \*\*\*  $P < 0.0005$ . Viral RNA was also measured in lung tissue homogenates  
836 of infected rhesus macaques at endpoint (14-17 dpi) and data is expressed as  $\log_{10}$  copies/gram  
837 of the lung tissue for random samples from three lobes in left (orange) and right (teal) lungs (c).  
838 Histopathologic analysis revealed regionally extensive interstitial lymphocytes, plasma cells,  
839 lesser macrophages and eosinophils expanding the alveolar septa (bracket) and alveolar spaces  
840 filled with macrophages (\*). Normal alveolar wall is highlighted (arrow) for comparison (d).  
841 Alveolar spaces with extensive interstitial alveolar wall thickening by deposits of collagen (\*) and  
842 scattered alveolar macrophages (arrow) (e). Viral RNA ( $\log_{10}$  copies/mL were measured by RT-  
843 PCR in BAL fluid (f) and Nasopharyngeal (g) swab from SARS-CoV-2 infected baboons. (n=6) One  
844 way Repeated-measures ANOVA with Geisser-Greenhouse correction for sphericity and Tukey's  
845 post hoc correction for multiple-testing (GraphPad Prism 8) was applied. Histopathologic analysis  
846 revealed regionally extensive interstitial lymphocytes, plasma cells, lesser macrophages and  
847 eosinophils expanding the alveolar septa (bracket) and alveolar spaces filled with macrophages  
848 (\*), (h). Alveolar wall thickening by interstitial deposits of collagen (\*), alveoli lined by occasional  
849 type II pneumocytes (arrowhead) and alveolar spaces containing syncytial cells (arrow) and  
850 alveolar macrophages (i). Viral RNA ( $\log_{10}$  copies/mL were measured by RT-PCR in marmoset



851 nasal wash (j) and oral (k) swabs longitudinally (red – 0 dpi; purple – 3 dpi; blue – 6 dpi; green –  
852 9 dpi; black – 14-17 dpi). n=6 for 0-3 dpi and n=4 for 6-14 dpi). .Histopathologic analysis revealed  
853 milder form of interstitial lymphocytes, and macrophages recruited to the alveolar space (m, n).  
854 Ordinary one-way ANOVA with Dunnett’s post hoc test was applied. Viral RNA was also measured  
855 in lung homogenates at endpoint (3 dpi & 14 dpi) and data is expressed as log<sub>10</sub> copies/gram of  
856 the lung for random samples from left and right lobes at 3 dpi (orange) and 14 dpi (teal) (g). Data  
857 is represented as mean± SEM. \*\* P<0.005, \*\*\*\* P<0.00005.

858

859

860

861

862

863

864

865

866

867

868


869

870

871

872





**Fig 4**

875 **Figure 5.** CXR (a) scores generated by a veterinary radiologist blinded to the experimental group  
876 (n=12) and (b) CXR scores split in old and young macaques (n=6). CXR radiographs showing  
877 minimal right caudal interstitial pattern at 0 dpi (c), Alveolar pattern associated with the caudal  
878 sub segment of the left cranial lung lobe and left caudal lung lobe with patchy right caudal  
879 interstitial opacity at 6 dpi (d) and Minimal left caudal interstitial pattern at 14dpi (e). CT (f) scores  
880 generated by a blinded veterinary radiologist (n=6). 3D reconstruction (g,k) of ROI volume  
881 representing the location of lesion. (h-j, l-n) represent image for quantification of lung lesion with  
882 green area representing normal intensity lung voxels (-850 HU to -500 HU), while red areas  
883 represent hyperdense voxels (-490 HU to 500 HU). Percent change in lung hyperdensity in SARS-  
884 CoV2 infected animals over 6 dpi compared to 12 dpi (o) (n=6). Data is represented as mean±  
885 SEM. (a) One way & (b) two way Repeated-measures ANOVA with Geisser-Greenhouse correction  
886 for sphericity and Tukey's post hoc correction for multiple-testing and (f,o) Paired T test  
887 (GraphPad Prism 8) was applied. \* P<0.005, \*\* P<0.005, \*\*\* P<0.0005.

888

889

890

891


892

893

894

895

896



898 **Figure 6. Longitudinal accumulation of myeloid cells in BAL following SARS-CoV-2 infection in**  
899 **rhesus macaques.** Flow cytometric analysis of BAL IMs (a, e), AMs (b, f), neutrophils (c,g), and  
900 pDCs (d, h). Data shown combined for age (a-d) (n=12); data split by age (g-h) (n=6). Data is  
901 represented as mean $\pm$  SEM. (a-d) One way and (e-h) two way Repeated-measures ANOVA with  
902 Geisser-Greenhouse correction for sphericity and Tukey's post hoc correction for multiple-testing  
903 (GraphPad Prism 8) was applied. \* P<0.005, \*\* P<0.005, \*\*\* P<0.0005. Coloring scheme for e-h  
904 – young (blue), old (red). Correlations with Spearman's rank test between cellular fraction and  
905 Log10 viral RNA copy number in BAL (i) and corresponding values for Spearman's rank correlation  
906 coefficient (j) and P value (Suppl. Fig13i). Coloring scheme for i – Neutrophil (blue), IM (red), AM  
907 (orange), pDC (green). Multilabel confocal immunofluorescence microscopy of FFPE lung sections  
908 from SARS CoV-2 infected Rhesus macaques having a high viral titer at 3 dpi (k-p) with SARS CoV-  
909 2 Spike specific antibody (green), KI-67<sup>29</sup>, neutrophil marker CD66abce (red) and DAPI (blue) at  
910 10X (k) and 63X (l); SARS CoV-2 Spike (green), pan-macrophage marker CD68 (red) and DAPI  
911 (blue) at 10X (m) and 63X (n); SARS CoV-2 Spike (green), HLA-DR<sup>29</sup>, pDC marker CD123 (red) and  
912 DAPI (blue) at 10X (o) and 63X (p).

913

914


915

916

917

918

919



921 **Figure 7. Longitudinal changes in T cells in BAL following SARS-CoV-2 infection in rhesus**  
922 **macaques.** BAL Frequencies of CD3<sup>+</sup> T cells (a), CD4<sup>+</sup> T cells (b), CD8<sup>+</sup> T cells (g), CD4<sup>+</sup> T cell subsets  
923 expressing early activation marker CD69 (c), CXCR3 (d), PD-1 (e) and memory marker CCR7 (f),  
924 CCR5 (l), HLA-DR (m) and LAG-3 (n); CD8<sup>+</sup> T cell subsets expressing early activation marker CD69  
925 (h), CXCR3 (i), PD-1 (j) and memory marker CCR7 (k), CCR5 (o), HLA-DR (p) and LAG-3 (q). Coloring  
926 scheme – young (blue), old (red). Data is represented as mean $\pm$  SEM. (n=6) Two way Repeated-  
927 measures ANOVA with Geisser-Greenhouse correction for sphericity and Tukey's post hoc  
928 correction for multiple-testing (GraphPad Prism 8) was applied. \* P<0.005, \*\* P<0.005, \*\*\*  
929 P<0.0005.

930

931

932

933

934

935

936

937

938


939

940

941

942





944 **Figure 8. Longitudinal changes in memory T cells in BAL following SARS-CoV-2 infection in**  
945 **rhesus macaques.** BAL Frequencies of CD4<sup>+</sup> T cell subsets expressing KI67 (a), Memory (b), Naïve  
946 (c), Effector (d), IL-2 (e) and Granzyme B (f). Frequencies of CD8<sup>+</sup> T cell subsets expressing KI67  
947 (g), Memory (h), Naïve (i), Effector (j), IL-2 (k) and Granzyme B (l). BAL cells were stimulated  
948 overnight (12-14 hours) with either Mock control (U); PMA-Ionomycin (P/I) or SARS-CoV-2 -  
949 specific peptide pools of the nucleocapsid (N), membrane (M) and spike (S) proteins. Antigen  
950 specific cytokine secretion in T cells was estimated by flow cytometry. Fraction of CD4<sup>+</sup> T cells  
951 secreting IL-2 (m), Granzyme B (n); CD8<sup>+</sup> T cells secreting IL-2 (o) and Granzyme B (p). Coloring  
952 scheme – young (blue), old (red). Data is represented as mean $\pm$  SEM. (n=6) two way Repeated-  
953 measures ANOVA with Geisser-Greenhouse correction for sphericity and Tukey's post hoc  
954 correction for multiple-testing (GraphPad Prism 8) was applied. \* P<0.005, \*\* P<0.005, \*\*\*  
955 P<0.0005.

956

957

958

959

960


961

962

963

964

965



967 **Figure S1. Clinical correlates in short-term (0-3 dpi) rhesus macaques.** Serum levels of tCO<sub>2</sub> (D-  
968 mmol/L) (a), and whole blood levels of Red Blood Cells (RBCs) (million/mL) (b), reticulocytes  
969 (K/mL) (c), White Blood Cells (WBCs) (K/mL) (d), platelets (K/uL) (e), Neutrophils (K/mL) (f),  
970 percentage of Neutrophils (g), percentage of monocytes (h). Viral RNA (log<sub>10</sub> copies/mL were  
971 measured by RT-PCR in saliva (i), and rectal swab (j). ) Data is represented as mean± SEM (n=4).  
972 One way Repeated-measures ANOVA with Geisser-Greenhouse correction for sphericity and  
973 Tukey's post hoc correction for multiple-testing (GraphPad Prism 8) was applied. \* P<0.005, \*\*  
974 P<0.005, \*\*\* P<0.0005.

975

976

977

978

979

980

981

982

983

984


985

986

987


988

Fig S1



990 **Figure S2. Gross and histopathologic findings of young and aged male and female Rhesus**  
991 **macaques experimentally exposed to COVID19 - 3 dpi.** Young male Rhesus macaque. Lung was  
992 grossly unremarkable (a). Aged male Rhesus macaque. Lung. The dorsal aspect of the lungs was  
993 mottled red (\*) (b). Aged male Rhesus macaque. Lung. Sub gross image showing extensive areas  
994 of consolidation (\*) (c). Aged male Rhesus macaque. Lung. Moderate interstitial pneumonia with  
995 scattered type II pneumocytes (arrow), neutrophils (arrowhead), and intra-alveolar fibrin  
996 deposition (\*) (d). Aged female Rhesus macaque. Lung. Mild interstitial pneumonia with  
997 scattered syncytial cells (arrow), neutrophils (arrowhead), and expansion of alveolar walls by  
998 fibrosis (bracket) (e). Young female Rhesus macaque. Lung. Vasculitis. Vascular wall disrupted by  
999 infiltrates of mononuclear cells and lesser neutrophils. Vessel lumen marked by (\*) (f). Young  
1000 female Rhesus macaque. Lung. Mild interstitial pneumonia. Alveolar spaces contain neutrophils  
1001 and cellular debris (necrosis, arrow) (g). Young female Rhesus macaque. Lung. Mild interstitial  
1002 pneumonia. Alveolar spaces (\*) contain neutrophils and eosinophilic fluid (edema) (h). Young  
1003 female Rhesus macaque. Lung. Bronchiolitis. Bronchiolar wall expanded by infiltrates of  
1004 lymphocytes and macrophages (bracket) (i). Young male Rhesus macaque. Lung. Bronchitis.  
1005 Bronchial wall expanded by infiltrates of eosinophils that expand and disrupt the epithelium and  
1006 smooth muscle (bracket) (j). Young female Rhesus macaque. Lung. Bronchitis. Bronchial lumen  
1007 contains macrophages (arrowhead), cellular debris, and syncytial cells (arrow) (k). Aged female  
1008 Rhesus macaque. Lung. Area of bronchiolar associated lymphoid tissue (BALT) (\*) (l). All slides  
1009 were stained with H&E.  
1010

**Fig S2**



1012 **Fig S3.** Multi-label confocal immunofluorescence microscopy of lungs (20X-a, 63X-g), nasal  
1013 epithelium (20X-b, 63x-h) and tonsil (20X-c,63X-i) with SARS CoV-2 N specific antibody (green),  
1014 DAPI (blue) and ACE-2 (red). Rabbit IgG isotype control antibody was used to rule out non-specific  
1015 staining in lungs (20X-d, 63X-j), nasal epithelium (20X-e, 63x-k) and tonsil (20X-f, 63X-l). Staining  
1016 in naïve rhesus macaque lung tissues did not show N signal in lungs (m) or nasal epithelium (n).

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028


1029

1030

1031

1032





1034 **Figure S4.** Multi-label confocal immunofluorescence microscopy of lungs (10X-a, 63X-g), nasal  
1035 epithelium (10X-b, 63x-h) and tonsil (10X-c,63X-i) with SARS CoV-2 S specific antibody (green)  
1036 and DAPI (blue). Rabbit IgG isotype control antibody was used to stain the tissues to rule out any  
1037 non-specific staining. The panels showing isotype control staining include: lungs (10X-d, 63X-j),  
1038 nasal epithelium (10X-e, 63X-k) and tonsil (10X-f, 63X-l).

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051


1052

1053

1054

1055

**Fig S4**



1060 **Figure S5. Radiology of Rhesus macaques experimentally exposed to COVID19 - 3 dpi. CXR**

1061 Radiographs showing ventrodorsal and right lateral views(a). Day 0: Normal, Day 1: Mild left  
1062 caudal interstitial opacity with minimal diffuse right interstitial opacity, Day 2: Mild multifocal  
1063 interstitial pattern (red arrow), Day 3: Mild multifocal interstitial pattern with patchy region in  
1064 left caudal lobe (red arrow). CT scan axial view showing lesion characteristics in rhesus macaques  
1065 infected with SARS-CoV-2 (b) at baseline and Day 1-3 dpi. As seen in (b) ground glass opacity seen  
1066 on Day 2 dpi intensified on Day 3 dpi. (c) and (d) show lesions that appear on Day 1 show gradual  
1067 resolution on Day 2-3 dpi whereas lesion in panel (e) observed on Day 1 dpi showed only minimal  
1068 changes on Day 2. Red arrow point towards lung lesions with high attenuation.

1069

1070

1071

1072

1073

1074

1075

1076

1077


1078

1079

1080

1081

**Fig S5**



1083 **Figure S6. SARS-CoV-2 induced cytokines in plasma.** Simultaneous analysis of multiple cytokines  
1084 by Luminex technology in the plasma of rhesus macaques over 0-3 dpi. Levels of IL-6 (a), IFN-a  
1085 (b), IFN-g (c), IL-8 (d), perforin (e), IP-10 (f), MIP1a (g), MIP1b (h), IL-12p40 (i), IL-18 (j), TNF-a (k)  
1086 and IL-1Ra (l) are expressed in Log<sub>10</sub> concentration in picogram per mL of plasma. (red – 0 dpi;  
1087 purple – 1 dpi; blue – 2 dpi; green – 3 dpi). (n=4) Data is represented as mean<sub>±</sub> SEM. One way  
1088 repeated-measures ANOVA with Geisser-Greenhouse correction for sphericity and Tukey's post  
1089 hoc correction for multiple-testing (GraphPad Prism 8) was applied. \* P<0.005, \*\* P<0.005, \*\*\*  
1090 P<0.0005.

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100


1101

1102

1103

1104

Fig S6



1106 Figure S7. Clinical correlates in long-term (14-17 dpi) rhesus macaques. Serum levels of CRP  
1107 (mg/L) (a), tCO<sub>2</sub> (D-mmol/L) (b), and whole blood levels of Red Blood Cells (RBCs) (million/mL)  
1108 (c), reticulocytes (K/mL) (d), percentage of Neutrophils (g), Neutrophils (K/mL) (f), platelets (K/uL)  
1109 (e), percentage of monocytes (h) and percent change in weight (i) (Coloring scheme for I – young  
1110 (blue), old (red)). (a-e) (n=12) Data is represented as mean<sub>±</sub> SEM. One way repeated-measures  
1111 ANOVA with Geisser-Greenhouse correction for sphericity and Tukey's post hoc correction for  
1112 multiple-testing (GraphPad Prism 8) was applied. \* P<0.005, \*\* P<0.005, \*\*\* P<0.0005.

1113

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123


1124

1125

1126

1127





1128

1129

1130

1131

1132 **Figure S8. Longitudinal viral RNA determination following SARS-CoV-2 infection in rhesus**  
1133 **macaques.** Viral RNA ( $\log_{10}$  copies/mL measured by RT-PCR in BAL fluid (a) and nasopharyngeal  
1134 (b), buccopharyngeal (c-d) and rectal<sup>30</sup> swabs longitudinally. Data is depicted as combined for  
1135 age (c,e) and data split by age a; b; d; f). Coloring scheme for c; e – (red – 0 dpi; purple – 3 dpi;  
1136 blue – 6 dpi; green – 9 dpi; orange – 12 dpi; black – 14-17 dpi). (n=12) One way Repeated-  
1137 measures ANOVA with Geisser-Greenhouse correction for sphericity and Tukey’s post hoc  
1138 correction for multiple-testing (GraphPad Prism 8) was applied. \*  $P<0.005$ , \*\*  $P<0.005$ , \*\*\*  
1139  $P<0.0005$ . Coloring scheme for a; b; d; f – young (blue), old (red). (n=6) Data is represented as  
1140 mean $\pm$  SEM. Two way Repeated-measures ANOVA with Geisser-Greenhouse correction for  
1141 sphericity and Tukey’s post hoc correction for multiple-testing (GraphPad Prism 8) was applied.  
1142 \*\*  $P<0.005$ .

1143

1144

1145

1146

1147

1148

1149


1150

1151

1152

1153

Fig S8



1155 **Figure S9. Longitudinal viral RNA determination following SARS-CoV-2 infection in rhesus**  
1156 **macaques.** Viral RNA was determined at endpoint in Lungs (a) and longitudinally in plasma (b)  
1157 and urine (c).

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

1170

1171

1172


1173

1174

1175

1176

Fig S9



**b**

Viral RNA (copies/mL) titre in plasma of Rhesus macaques

ID	Sex	Cohort	Day 0	Day 3	Day 6	Day 9	Day 12
16653	M	old	*UD	*UD	*UD	*UD	*UD
17736	F	old	*UD	*UD	*UD	*UD	*UD
19314	F	old	*UD	*UD	*UD	*UD	*UD
19853	F	old	*UD	*UD	*UD	*UD	*UD
20083	F	old	*UD	*UD	*UD	*UD	*UD
33926	M	old	*UD	*UD	*UD	*UD	*UD
35951	M	juvenile	TBD	*UD	*UD	*UD	*UD
35969	M	juvenile	*UD	*UD	*UD	*UD	*UD
36052	F	juvenile	TBD	*UD	*UD	*UD	*UD
36056	F	juvenile	*UD	*UD	*UD	*UD	*UD
36189	F	juvenile	*UD	*UD	*UD	*UD	*UD
36207	M	juvenile	TBD	*UD	*UD	*UD	*UD

**c**

Viral RNA (copies/mL) titre in urine of Rhesus macaques

SNPRC ID	Sex	Cohort	Day 0	Day 3	Day 6	Day 9	Day 12
16653	M	old		*UD		*UD	
17736	F	old		*UD		*UD	
19314	F	old					
19853	F	old					
20083	F	old					
33926	M	old		*UD		*UD	
35951	M	juvenile				*UD	
35969	M	juvenile		*UD		*UD	
36052	F	juvenile		*UD		*UD	
36056	F	juvenile		*UD		*UD	
36189	F	juvenile					

1177

1178

1179


1180 **Figure S10. Gross and histopathologic findings of young and aged male and female Rhesus**  
1181 **macaques experimentally exposed to SARS-CoV-2 - 14-17 dpi.** Young male Rhesus macaque.  
1182 Lung was grossly unremarkable (a). Aged male Rhesus macaque. The dorsal aspect of the lungs  
1183 was mottled red (b). Young male Rhesus macaque. Lung. Subgross image showing multifocal  
1184 areas of minimal interstitial pneumonia (\*) (c). Young female Rhesus macaque. Lung. Mild  
1185 lymphocytic interstitial pneumonia with alveolar septa (bracket) expanded by mononuclear cells  
1186 (lymphocytes and macrophages) (d). Aged female Rhesus macaque. Lung. Mild lymphocytic  
1187 interstitial pneumonia with increased alveolar macrophages and few syncytial cells (arrow)  
1188 within the alveolar lumen (\*; a neutrophil is just to the left of the \*) and type II pneumocytes  
1189 lining alveoli (arrowhead) (e). Aged female Rhesus macaque. Lung. Minimal interstitial  
1190 pneumonia with alveolar septa expanded by fibrosis (\*) and few syncytial cells (arrow) within  
1191 alveoli (f). Young male Rhesus macaque. Lung. Alveolar septa expanded by fibrosis (\*) and  
1192 lymphocyte infiltrates (g). Aged male Rhesus macaque. Lung. Areas of bronchiolization (arrows)  
1193 (h). Young female Rhesus macaque. Lung. Vasculitis. Vascular wall disrupted by infiltrates of  
1194 mononuclear cells and lesser neutrophils (arrow) (i). Young female Rhesus macaque. Lung.  
1195 Bronchitis. Bronchial epithelium infiltrated by eosinophils (arrow). Fibrosis adjacent to bronchus  
1196 (\*) (j). Young female Rhesus macaque. Lung. Area of perivascular lymphocyte infiltrates (\*) (k).  
1197 Young female Rhesus macaque. Lung. Area of bronchiolar associated lymphoid tissue (BALT) (\*)  
1198 (l). All slides were stained with H&E.

1199

1200

1201

**Fig S10**



1203 **Figure S11. Viral, Gross and histopathologic findings of young male and female baboons**  
1204 **experimentally exposed to COVID19 - 14-17 dpi.** Viral RNA ( $\log_{10}$  copies/mL were measured by  
1205 RT-PCR in buccopharyngeal (a) and rectal (b) swabs longitudinally. Young male baboon. The  
1206 dorsal aspect of the lungs was mottled red (\*) (c). Young female baboon. The dorsal aspect of the  
1207 lungs was mottled red (\*) (d). Young male baboon. Lung. Subgross image showing areas of  
1208 consolidation (\*) (e). Young female baboon. Moderate lymphocytic interstitial pneumonia with  
1209 scattered neutrophils (arrowhead) (f). Young female baboon. Moderate lymphocytic interstitial  
1210 pneumonia with alveolar septa (bracket) markedly expanded by mononuclear cells (lymphocytes  
1211 and macrophages) and increased alveolar macrophages within the alveolar lumen (\*) (g). Young  
1212 male baboon. Lung. Mild lymphocytic interstitial pneumonia with increased alveolar  
1213 macrophages and few syncytial cells (arrow) within the alveolar lumen (\*) (h). Young female  
1214 baboon. Mild lymphocytic interstitial pneumonia with scattered type II pneumocytes (arrows)  
1215 and increased alveolar macrophages and neutrophils within the alveolar lumen (\*) (i). Young  
1216 male baboon. Lung. Alveolar septa expanded by fibrosis (\*) (j). Young male baboon. Lung.  
1217 Alveolar septa expanded by fibrosis (\*) (k). Young female baboon. Area of bronchiolization  
1218 (bracket) (l). Young male baboon. Lung. Syncytial cells within airways (arrows) (m). Young male  
1219 baboon. Lung. Bronchitis. Bronchial wall expanded by infiltrates of eosinophils that expand and  
1220 disrupt the epithelium (arrow). Area of bronchiolar associated lymphoid tissue (BALT) (\*) (n). All  
1221 slides were stained with H&E.


1222

1223

1224



1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246



1247 **Figure S12.** CT scan in axial view showing lesion characteristics in rhesus macaques infected with  
1248 SARS-CoV-2 from Day 6-12 dpi. As seen in panel A, B, D, E and F patchy alveolar patterns, nodular  
1249 and/or multifocal ground glass opacities (red arrow) seen on Day 6 dpi show dramatic resolution  
1250 by Day 12 dpi, whereas panel C shows persistent patchy ground glass opacity on Day 6 dpi and  
1251 Day 12 dpi.

1252

1253

1254

1255

1256

1257

1258

1259

1260

1261

1262

1263


1264

1265

1266

1267

1268



1270 **Figure S13.** Accumulation of various types of myeloid cells in BAL (a-d) and PBMCs (c-h). Total  
1271 myeloid cell compartment in the BAL in all animals (a) (n=12), and in two groups of macaques  
1272 split by age (b). percentage of cDCs (c) and intermediate monocytes (d) in BAL. Percentage of  
1273 interstitial (e) and alveolar (f) macrophages, pDCs (g) and intermediate macrophages (h) in the  
1274 peripheral blood. Coloring scheme for b-h – young (blue), old (red) (n=6). (i) P value table for  
1275 Spearman’s correlation curve in Fig 5i.

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286


1287

1288

1289

1290

1291



1293 **Figure S14. Detection of SARS-CoV-2 signal in host lung cells by confocal microscopy.** Multi-label  
1294 confocal immunofluorescence microscopy of a high viral titer lung lobe from SARS CoV-2 infected  
1295 Rhesus macaque at 3 dpi with SARS CoV-2 Spike specific antibody (green), neutrophil marker  
1296 CD66abce (red) and DAPI (blue)- (10X-a, 63X-g) vs the naïve control lungs (10X-d, 63X-j). SARS  
1297 CoV-2 Spike (green), pan-macrophage marker CD68 (red) and DAPI (blue) in infected lungs (10X-  
1298 b and 63X-h) vs the naïve control lungs (10X-e, 63X-k). SARS CoV-2 Spike (green), HLA-DR <sup>29</sup>, pDC  
1299 marker CD123 (red) and DAPI (blue) specific staining in infected lungs (10X-c,63X-i) vs naïve  
1300 control lungs(10X-f, 63X-l).

1301

1302

1303

1304

1305

1306

1307

1308

1309


1310

1311

1312

1313

1314




**Fig S14**

1316 **Figure S15. Longitudinal changes in cytokine secretion profile in BAL T cells following SARS-CoV-**  
1317 **2 infection in rhesus macaques.** BAL Frequencies of CD4<sup>+</sup> T cell subsets expressing Interferon- $\gamma$   
1318 (a), IL-17 (b), TNF- $\alpha$  (c), CD8<sup>+</sup> T cells expressing Interferon- $\gamma$  (d), IL-17 (e), TNF- $\alpha$  (f) cultured  
1319 overnight without any external antigenic stimulation. BAL cells were also stimulated overnight  
1320 (12-14 hours) with either Mock control (U); PMA-Ionomycin (P/I) or SARS-CoV-2 -specific peptide  
1321 pools of the nucleocapsid (N), membrane (M) and spike (S) proteins. Antigen specific cytokine  
1322 secretion in T cells was estimated by flow cytometry. Fraction of CD4<sup>+</sup> T cell subsets expressing  
1323 Interferon- $\gamma$  (g), IL-17 (h), TNF- $\alpha$  (i), CD8<sup>+</sup> T cells expressing Interferon- $\gamma$  (j), IL-17 (k), TNF- $\alpha$  (l).  
1324 Coloring scheme– young (blue), old (red). Data is represented as mean $\pm$  SEM. (n=6) Two way  
1325 Repeated-measures ANOVA with Geisser-Greenhouse correction for sphericity and Tukey's post  
1326 hoc correction for multiple-testing (GraphPad Prism 8) was applied. \* P<0.005, \*\* P<0.005, \*\*\*  
1327 P<0.0005.  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336



**Fig S15**



1338 **Figure S16. Longitudinal changes in SARS-CoV-2 induced cytokines in BAL fluid and plasma**  
1339 **following SARS-CoV-2 infection in rhesus macaques over two weeks.** Simultaneous analysis of  
1340 multiple cytokines by Luminex technology in the BAL fluid and plasma of rhesus macaques over  
1341 0-15 dpi. Levels of IFN- $\alpha$  (a), IL-1Ra (b), IFN- $\gamma$  (c), TNF- $\alpha$  (d), IL-6 (e), Perforin (f) are expressed in  
1342 Log<sub>10</sub> concentration in picogram per mL of BAL fluid. Levels of IFN- $\alpha$  (g), IL-1Ra (h), IFN- $\gamma$  (i), TNF-  
1343 a (j), IL-6 (k), Perforin (l) are expressed in Log<sub>10</sub> concentration in picogram per mL of BAL fluid.  
1344 Coloring scheme – young (blue), old (red). Data is represented as mean $\pm$  SEM. (n=12) Two way  
1345 Repeated-measures ANOVA with Geisser-Greenhouse correction for sphericity and Tukey's post  
1346 hoc correction for multiple-testing (GraphPad Prism 8) was applied. \* P<0.005, \*\* P<0.005, \*\*\*  
1347 P<0.0005.

1348

1349

1350

1351

1352

1353

1354


1355

1356

1357

1358

1359



1361 **Figure S17. SARS-CoV-2 infection induces ACE-2 expression.** RNAseq was performed on total  
1362 RNA isolated from the lungs of naïve (n=3) and SARS-CoV-2 infected (14-17dpi) rhesus macaques  
1363 (n=8, 3 young and 5 old macaques) as described earlier <sup>16</sup>. Results indicate that the expression of  
1364 ACE2, which is lower in naïve animals (denoted by red color in the heat map) (a), was induced  
1365 following SARS-CoV-2 infection (denoted by blue color in the heat map) (a). Relative expression  
1366 level of ACE-2 was significantly higher than in naïve tissues (b). Higher expression of ACE-2 was  
1367 observed in lung tissues obtained at necropsy from young relative to old macaques (c, d), such  
1368 that the difference between naïve animals and young SARS-CoV-2 infected animals in ACE-2  
1369 expression levels was statistically significant by itself. All p-values shown on expression swarm  
1370 plots (b-d) are FDR-corrected significance values for differential expression calculated by DESEQ2  
1371 <sup>16</sup>.

1372

1373

1374

1375

1376

1377

1378


1379

1380

1381

1382

**Fig S17**



1384 **Figure S18. Flow cytometry Gating Strategy.** Gating strategy for T cell phenotyping is described.

1385

1386

1387

1388

1389

1390

1391

1392

1393

1394

1395

1396

1397

1398

1399

1400

1401

1402


1403

1404


1405

**Fig S18**

**Gating Strategy: T Cell Phenotyping**



**Gating Strategy: Myeloid Phenotyping**



1407 **Supplemental tables**

1408

1409 **Table S1.** In vivo experimental design. A. short-term rhesus macaque pilot. B-D. 14-day  
1410 multispecies comparison in rhesus macaques, baboons, marmosets.

1411

1412 **Table S2.** Distribution of lesions by anatomic location and morphologic diagnosis of young and  
1413 aged rhesus macaques experimentally exposed to SARS-CoV-2 - 3 dpi.

1414

1415 **Table S3.** Distribution of lesions by anatomic location and morphologic diagnosis of young and  
1416 aged rhesus macaques experimentally exposed to SARS-CoV-2 – 14-17 dpi.

1417

1418 **Table S4.** Distribution of lesions in baboons experimentally exposed to SARS-CoV-2 – 14-17 dpi.

1419

1420 **Table S5.** CXR scores in rhesus macaques experimentally exposed to SARS-CoV-2 – 14-17 dpi.

1421

1422 **Table S6.** CT scores in rhesus macaques experimentally exposed to SARS-CoV-2 – 14-17 dpi.

1423

1424 **Table S7.** List of antibodies used for immunophenotyping studies.

1425

1426

1427